Modern Medical Genetics and Genomics by unknown
Modern Medical  
Genetics and Genomics
Edited by Israel Gomy
Edited by Israel Gomy
The field of medical genetics and genomics has been constantly revolutionized by 
new breakthroughs, which bring more knowledge into the etiology and help improve 
the health care of individuals with either rare or common diseases. Nevertheless, 
as technologies evolve, novel challenges emerge, both technically and ethically, so 
they must be prudentially addressed. Among the myriad applications of genomics in 
medicine, this book depicts a glimpse of the advances achieved that have been leading 
us to the personalized/precision medicine era.
Published in London, UK 
©  2019 IntechOpen 









Modern Medical Genetics 
and Genomics
Edited by Israel Gomy
Published in London, United Kingdom

Supporting open minds since 2005
Modern Medical Genetics and Genomics
http://dx.doi.org/10.5772/intechopen.76597
Edited by Israel Gomy
Contributors
Esther Lopez-Bayghen, Almena Lopez-Luna, Dinorah Hernandez-Melchor, Leticia Ramirez, Rodney Scott, 
Tom Nolis, Isam Al Jashi, Al Jashi Cristina Gladys, Leonardo Porchia, Elizbeth Schaeffer, Israel Gomy
© The Editor(s) and the Author(s) 2019
The rights of the editor(s) and the author(s) have been asserted in accordance with the Copyright, 
Designs and Patents Act 1988. All rights to the book as a whole are reserved by INTECHOPEN LIMITED. 
The book as a whole (compilation) cannot be reproduced, distributed or used for commercial or 
non-commercial purposes without INTECHOPEN LIMITED’s written permission. Enquiries concerning 
the use of the book should be directed to INTECHOPEN LIMITED rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons 
Attribution 3.0 Unported License which permits commercial use, distribution and reproduction of 
the individual chapters, provided the original author(s) and source publication are appropriately 
acknowledged. If so indicated, certain images may not be included under the Creative Commons 
license. In such cases users will need to obtain permission from the license holder to reproduce 
the material. More details and guidelines concerning content reuse and adaptation can be found at 
http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not 
necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of 
information contained in the published chapters. The publisher assumes no responsibility for any 
damage or injury to persons or property arising out of the use of any materials, instructions, methods 
or ideas contained in the book.
First published in London, United Kingdom, 2019 by IntechOpen
IntechOpen is the global imprint of INTECHOPEN LIMITED, registered in England and Wales, 
registration number: 11086078, 7th floor, 10 Lower Thames Street, London,  
EC3R 6AF, United Kingdom
Printed in Croatia
British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library
Additional hard and PDF copies can be obtained from orders@intechopen.com
Modern Medical Genetics and Genomics




eBook (PDF) ISBN 978-1-83968-144-8
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,500+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Dr. Israel Gomy graduated in Medicine at Pontificia Universidade 
Católica do Paraná, Curitiba, Brazil. He received his Master’s 
degree in Biomedical Research at Universidade de São Paulo, 
Ribeirão Preto, Brazil, and his PhD in Oncology at Fundação 
Antônio Prudente, São Paulo, Brazil. Dr. Gomy is an assistant 
professor at Faculdades Pequeno Príncipe, Curitiba, Brazil, and 
an assistant physician at Hospital de Clínicas da Universidade 
Federal do Paraná, Curitiba, Brazil. He is also a postdoctoral researcher in medical 










Reproductive and Prenatal Genetics 9
Chapter 2 11
The Genetic and Biochemical Blueprint of Endometrial Receptivity: Past,  
Present, and Future Factors Involved in Embryo Implantation Success
by Almena López-Luna, Dinorah Hernández-Melchor, Leticia Ramírez-Martínez  
and Esther López-Bayghen
Chapter 3 37
Aneuploidy Rates Inversely Correlate with Implantation during In Vitro 
Fertilization Procedures: In Favor of PGT
by Elizabeth Schaeffer, Leonardo Porchia, Almena López-Luna,  
Dinorah Hernández-Melchor and Esther López-Bayghen
Chapter 4 57
Screening (Bi Test, Triple Test, Panorama Test) and Amniocentesis for Early 
Diagnosis of Congenital Malformations




Genetic Contributors to Hereditary Cancer Predispositions: Do We Have  
Enough Information?










Reproductive and Prenatal Genetics 9
Chapter 2 11
The Genetic and Biochemical Blueprint of Endometrial Receptivity: Past,  
Present, and Future Factors Involved in Embryo Implantation Success
by Almena López-Luna, Dinorah Hernández-Melchor, Leticia Ramírez-Martínez 
and Esther López-Bayghen
Chapter 3 37
Aneuploidy Rates Inversely Correlate with Implantation during In Vitro 
Fertilization Procedures: In Favor of PGT
by Elizabeth Schaeffer, Leonardo Porchia, Almena López-Luna,  
Dinorah Hernández-Melchor and Esther López-Bayghen
Chapter 4 57
Screening (Bi Test, Triple Test, Panorama Test) and Amniocentesis for Early 
Diagnosis of Congenital Malformations




Genetic Contributors to Hereditary Cancer Predispositions: Do We Have 
Enough Information?
by Tom Nolis and Rodney J. Scott
Preface
The field of medical genetics and genomics is undergoing a constant revolution
based on new breakthroughs that bring increasing insights into the etiology of rare
and common diseases, which help improve the health care of individuals with these
disorders.
The development of high-throughput technologies such as next-generation
sequencing (NGS) has enabled the detection of inherited susceptibilities and 
actionable mutational profiles of tumors for tailored therapies and management. 
Additionally, the generation of such massive amounts of data has prompted 
advances in the field of bioinformatics, with regard to complex tools and numerous
databases to guide the interpretation of such big data, and to deal with noninforma-
tive results such as the notorious variants of uncertain significance. Besides these
technical challenges, important ethical issues must also be considered: for example, 
the disclosure of results from prenatal and newborn screening through NGS, and 
findings from population-level screening of asymptomatic individuals. Addressing 
such challenges is not easy. We propose that investigators must provide tentative
answers for one vital question: What is the analytic validity, clinical validity, and 
clinical utility of genetic testing?
This book aims to depict some of the myriad applications of genetics and genomics
in the practice of medicine. We present the material in three sections: (1) an intro-
ductory landscape of medical genetics and genomics and portraits of personalized 
genomic medicine; (2) the field of reproductive genetics and prenatal screening: the
first two chapters of this section deal with the most critical factors involved in the
success of embryo implantation through assisted reproductive technology, includ-
ing endometrial receptivity and rates of embryonic aneuploidy; the third chapter
evaluates the accuracy of invasive and noninvasive prenatal screening for predict-
ing the risk of fetal malformations; and (3) the area of hereditary cancer genetics, 
wherein is presented an updated review of the clinical utility of genetic testing, as
exemplified by the description of hereditary breast and ovarian cancers.
Even though the information presented here offers a very limited look at the
modern-day developments and breakthroughs of the centenarian field of medical 
genetics, this book nevertheless provides an important glimpse of the fascinating 
and challenging era of personalized or precision medicine.
Israel Gomy
Universidade Federal do Paraná,
Curitiba, Brazil
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Modern medical genetics as a well-defined field of medicine has developed so 
fast since its origins half a century ago that we cannot bear in mind how long time 
ago its roots and beginnings came from.
It can be argued that genetics overall was based on measuring the problems 
of human hereditary features and inherited diseases, since before the twentieth-
century acceptance of Mendelian laws of heredity. Thus, medical genetics, viewed 
from its broadest perspective, is perhaps the oldest area of genetics and not a recent 
area that it is sometimes believed.
2. Modern genomics in medicine
During the years, with developments in cellular and molecular biology, the 
field of medical genetics expanded from a small clinical subspecialty focused at 
describing a few rare hereditary disorders to a recognized medical specialty whose 
principles and approaches are essential parts of the diagnosis and management of 
many disorders, both common and rare. These genetic concepts and approaches are 
not restricted to any one medical specialty or subspecialty, as they permeate many, 
and perhaps all areas of medicine.
The medical geneticist is usually a physician who works as part of a team of 
clinical providers, including many other physicians, nurses, and genetic counselors, 
to evaluate patients and their relatives for possible hereditary diseases. They char-
acterize the patient (or proband) through analyses of personal and family history 
and physical examination; assess risk and possible modes of inheritance; indicate 
diagnostic testing; manage prevention, treatment, and surveillance; and participate 
in communicating to other family members at risk for the disorder.
During the twentieth century, it gradually became clear that hereditary fac-
tors were implicated in many conditions and that different genetic mechanisms 
were involved. Virtually, any disease is the result of the interaction of genes and 
environment, but the relative influence of the genetic component may be large or 
small. Traditionally, genetic conditions have been classified into three categories: 
monogenic, chromosomal, and multifactorial disorders. However, it is becoming 
increasingly evident that the interplay of different genes (polygenic inheritance) 
is essential in disease and that an additional category—acquired somatic genetic 
disease—should also be included.
Improvements in all areas of medicine, mainly public health and therapeutics, 
resulted in modifying patterns of diseases, with improving recognition of the role 
3
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of genetic factors for most of common disorders or even for the susceptibility to 
infectious diseases. For complex chronic degenerative diseases of adult onset, their 
overall contribution of heritability has been identified, as life expectancy increases 
and high-throughput technologies improve. These provide the opportunity for 
understanding the interactions between the genetic and environmental factors of 
diseases such as cancer, Alzheimer’s disease, diabetes mellitus, macular degenera-
tion, and cardiomyopathy.
In recent years, we have been facing the applications of modern genomics to the 
practice of medicine. With robust molecular biology technologies, one can identify 
the actionable mutations present in a tumor and establish the profile of its pattern 
of RNA expression, which are currently being used for determining prognosis and 
choosing appropriate targeted therapies for individual cancer patients. Another 
application is how modern genomic approaches are increasing our abilities in risk 
assessment and helping provide more accurate genetic counseling to patients and 
families affected with hereditary diseases as well as advances in prenatal diagnosis.
There are further examples of applications of genomics to individualized health 
care: screening asymptomatic individuals for genetic predisposition to various diseases 
in order to improve health care, population-based newborn screening for preventable 
and treatable genetic diseases, identifying couples that are carriers for autosomal reces-
sive or X-linked diseases that could affect their children before conception, prenatal 
screening of the fetus for aneuploidy by maternal cell-free DNA, and applications of 
pharmacogenomics on the detection of individual variation affecting drug therapy, 
which can be used to improve therapeutic efficacy and reduce adverse events.
At the beginning of the twenty-first century, the Human Genome Project (HGP) 
provided a virtually complete sequence of human genome from which now derives the 
efforts to catalog all human genes, understand their structure and regulation, deter-
mine the extent of their variation in different populations, and uncover how genetic 
variation contributes to susceptibility. The whole genome of any individual can now be 
sequenced rather than sequencing one gene at a time. These achievements are making 
possible the practice of genomic medicine, which aims at applying a wide analysis of the 
human genome and its products, including the epigenetic regulation of gene expres-
sion, gene variation, and their interactions with the environment, to medical care.
The HGP has now been succeeded by the Human Variome Project, which seeks 
to compile and share the huge variation in human DNA sequence worldwide. This 
is potentially possible since whole exome sequencing (WES) and whole genome 
sequencing (WGS) have been increasingly performed in several population studies. 
For example, the 100,000 Genomes Project in the United Kingdom have recently 
achieved its goal of 100,000 genomes sequenced [1].
The study of genetics and its role in causing human disease is now widely 
acknowledged as being among the most exciting and influential areas of medical 
research. Certainly, their valuable discoveries have benefited patients and families 
dramatically, but this achievement will be measured by translating them into both 
treatment and prevention of disease.
3. Diagnostic advances
Advances over the past few years in mutation identification have provided 
many improvements in risk assessment, carrier detection, and prenatal diagno-
sis, allowing the detection of particular mutations with almost 100% accuracy. 
Laboratory testing for pathogenic (disease-causing) mutations is available for 
more than 4,500 genes associated to over 11,000 genetic conditions [2]. The 
better knowledge of the genes involved in hereditary disease and the rapidly 
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cheaper cost of DNA sequencing have permitted the identification of mutations in 
a patient or family member, and, therefore, the molecular diagnosis has become 
the standard of care for many conditions. DNA samples for testing are available 
not only from readily accessible tissues, such as a buccal scraping or blood sample, 
but also from tissues obtained by more invasive testing, such as chorionic villus 
sampling or amniocentesis.
For many hereditary disorders (including retinal degeneration, deafness, 
hereditary breast and ovarian cancer, Lynch syndrome, congenital myopathy, 
mitochondrial disorders, and hypertrophic or dilated cardiomyopathies), there is a 
substantial locus heterogeneity, that is, numerous genes are known to be mutated 
in different families with these disorders. When a patient with one of these highly 
heterogeneous disorders seeks for testing, recent advances in DNA sequencing make 
it possible to analyze large panels of dozens to more than 100 genes simultaneously 
and cost-effectively for mutations in every gene in which mutations have been seen 
previously to cause the disorder.
In those conditions for which even a large panel of relevant genes cannot be 
formulated for a particular phenotypically defined disorder, or for those geneti-
cally heterogeneous entities (e.g. intellectual disability, autism spectrum disorder) 
genetic diagnosis still can be achieved by analyzing all the coding exons of every 
gene (by WES) or by sequencing the entire genome (by WGS) to identify patho-
genic mutations.
The use of large gene panels and, even more so, WGS or WES raises special 
issues for sequence interpretation and risk assessment. As there are more genes 
being tested, the number of sequence differences between a patient’s DNA and that 
of an arbitrary reference sequence also increases; consequently, many previously 
undescribed variants will be found whose pathogenicity is unknown. These are 
so-called variants of uncertain significance (VUSs). This is the case, for example, of 
a missense mutation that results in the substitution of one amino acid for another in 
the encoded protein.
Thus, the interpretation of variants is a challenging and demanding area for all 
professional geneticists who provide molecular diagnosis. The American College of 
Medical Genetics and Genomics has recommended that variants be categorized into 
one of five classes: pathogenic, likely pathogenic, of uncertain significance, likely 
benign, and benign variants [3] Specialists in molecular diagnostics, human genom-
ics, and bioinformatics have developed a series of criteria for addressing the muta-
tion status. In most cases, none of these criteria is absolutely definitive but must 
be considered together to provide an overall assessment of the pathogenicity of a 
variant. Only those variants with a high probability of being pathogenic are com-
municated to the health professional and patient. It is arguable whether the testing 
laboratory should disclosure all VUSs, at the same time remaining available for 
updating as new information allow reclassification as either benign or pathogenic.
Despite all the time and effort put into interpretation, it is still impossible to 
ensure any clinical significance to the vast majority of all variants found through 
next-generation sequencing (NGS). There is a general concern that individuals and 
their clinical providers, when confronted with VUSs, will require additional unnec-
essary testing, with the potential for finding results with even more VUSs, thereby 
increasing patient’s uncertainty and anxiety. Moreover, there is the additional 
concern that even when a variant is known to be pathogenic and highly penetrant in 
families with multiple affected individuals, the true penetrance of a variant when it 
is found in individuals with a negative family history may be much lower.
Therefore, risk assessment and genetic counseling in this context are challenging 
processes and depend on continually addressing recently available information and 
communicating it properly to healthcare providers and patients.
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4. Ethical dilemmas
Each new advance in genetic technology has simultaneously brought new ethical 
concerns and raised new dilemmas about how science will be applied and utilized in 
medicine. At the center of this is the recognition that an individual’s genetic back-
ground is fundamental to both their identity and possible disease susceptibility. The 
most controversial field is prenatal genetics and reproductive choice, though national 
legal frameworks and cultural practices vary widely worldwide. The debate sur-
rounding the early ability to perform prenatal diagnosis for Down syndrome through 
invasive procedures in the mid-1960s is compared to the new technology that makes 
it possible to perform detailed genetic screening of the fetus on cell-free fetal DNA 
in the maternal blood or on embryos created through in vitro fertilization for preim-
plantation genetic diagnosis (PGD). Great controversy has taken place, and will go 
on, regarding the disclosure of unexpected but significant “incidental findings” from 
WES or WGS carried out for specific clinical purposes [4]. Furthermore today there is 
the technical feasibility of all newborns having their genome sequenced and screened 
for either childhood disorders or adult-onset conditions [5].
Advances in genetics attract great media attention, and this has brought the 
ethical debate to a wide public scenario. Issues about insurance, forensic science and 
DNA databases, patenting, gene therapy, population screening, cloning, stem cell 
research, and hybrids are considered to have major societal, commercial, and politi-
cal importance and therefore impact clinical and laboratory practice in medical 
genetics. On a global scale, it is essential to safeguard fundamental principles such 
as privacy, confidentiality, and respect for human life at all stages and ages.
Many of the questions raised do not have easy or definitive answers, which 
means that there will be a great need for both public awareness and properly trained 
clinicians and counselors to balance the needs of their patients and families with 
these ethical challenges for the foreseeable future.
5. Personalized and precision medicine
The aim of personalized or individualized medicine is to use knowledge of 
an individual’s genetic (or genomic) background relevant to the maintenance of 
health, prevention, and treatment of diseases as a routine part of medical care.
During the past 10 years, many examples of stratified medicine have blossomed, 
where the therapy of a particular disease is dependent on the germline or somatic 
variants patients may carry. These examples include monogenic rare diseases where a 
different treatment is recommended for patients with some types of germline muta-
tions in a specific gene, such as CFTR gene mutations that cause cystic fibrosis, and 
the molecular therapy targeted on an actionable somatic mutation of a specific tumor, 
such as the BRAF V600E mutation in malignant melanoma. The genetic (or genomic) 
diagnosis is therefore a crucial step toward the most appropriate treatment and/or 
prevention, what is so-called clinical utility or actionability [6, 7]. Recent initiatives 
are focusing on improving health outcomes through precision medicine especially in 
Oncology [8] (Table 1). This is a multidisciplinary integrated approach that analyzes 
human samples and personal data to improve health care through increased precision 
in the knowledge of mechanisms of both disease and drug response.
Personalized genomic medicine (PGM) is only one component of precision 
medicine, which means, in a broadest sense, it requires clinical care providers to 
combine genomic information with other types of information, such as biochemi-
cal or physiological testing results, neurodevelopmental history, environmental 
exposures, and psychosocial experiences. The most important goal is provide more 
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precise diagnosis, genetic counseling, management, prevention, and therapy. This 
effort has already got started, but plenty of work still needs to be done before PGM 
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Tumor(s) Genes Clinical application(s)
Melanoma BRAF, CDKN2A, KIT Therapy; risk assessment; inherited 
susceptibility 
Breast and ovarian cancer BRCA1, BRCA2 Therapy; inherited susceptibility
Colorectal cancer MLH1, MSH2, MSH6, PMS2, 
EPCAM, BRAF, KRAS, NRAS
Therapy; inherited susceptibility
Non-small-cell lung cancer EGFR, BRAF, KRAS, ERBB2, RET, 
MET, ALK, ROS1
Therapy
Myelodisplastic syndrome TP53, GATA2, JAK2, ASXL1, ETV6, 
RUNX1, SF3B1, EZH2
Diagnosis; risk stratification
Acute myeloid leukemia KIT, CEBPA, FLT3, NPM1 Risk stratification
Table 1. 
Genetic/genomic profiling for selected malignancies (adapted from [8]).
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4. Ethical dilemmas
Each new advance in genetic technology has simultaneously brought new ethical 
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cal or physiological testing results, neurodevelopmental history, environmental 
exposures, and psychosocial experiences. The most important goal is provide more 
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precise diagnosis, genetic counseling, management, prevention, and therapy. This 
effort has already got started, but plenty of work still needs to be done before PGM 
becomes integrated into medicine itself.
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In the field of assisted reproductive technology, endometrial receptivity is a 
crucial aspect that affects implantation rates in in-vitro fertilization procedures; 
in fact, impaired endometrial receptivity has been identified as the rate-limiting 
step for favorable pregnancy outcomes once factors regarding embryo quality have 
been optimized. The endometrium is a dynamic tissue that undergoes proliferative 
and secretory changes in each menstrual cycle, acquiring a short and transient 
period of embryo receptivity known as the Window of Implantation. Precise 
embryo-endometrial synchrony is necessary to achieve a successful pregnancy, 
and it involves complex and multifactorial processes related to morphological, 
biochemical, and genetic changes. On that behalf, defining the receptive window 
of each patient for personalized embryo transfer is a current goal. Here, we review 
different indicators of endometrial receptivity throughout the menstrual cycle, 
spotlighting the opening of the window of implantation: classical histological 
and biochemical markers, genetic factors, leading-edge transcriptomic signatures 
and miRNA profiles, and novel features such as the microbiome and secretome. 
Understanding the molecular mechanisms behind endometrial receptivity will 
facilitate the optimization and improvement of infertility treatments.
Keywords: endometrial receptivity, embryo implantation, menstrual cycle, window 
of implantation, decidualization
1. Introduction
The field of assisted reproductive technology (ART) has grown significantly in 
use and understanding over the past few decades, nevertheless, the rates of suc-
cessful pregnancies in in-vitro fertilization (IVF) procedures are still relatively low. 
Impaired endometrial receptivity (ER) has been identified as the rate-limiting step 
for favorable pregnancy outcomes once all other factors, including the acquisi-
tion and selection of the best quality embryo(s), have been optimized. Correct 
and synchronized maturation of the endometrial tissue is essential for embryo 
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and synchronized maturation of the endometrial tissue is essential for embryo 
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implantation [1, 2]. The endometrium is a dynamic tissue that undergoes prolifera-
tive and secretory changes in each menstrual cycle. Throughout most of this cycle, 
the endometrium remains “non-adhesive” to embryos and it only acquires a short 
and transient period of embryo receptivity known as the “window of implantation” 
(WOI) [3, 4]. In humans, during a natural cycle, the endometrium becomes recep-
tive 6 to 8 days after ovulation and it remains receptive for approximately 24–48 
h, this time is assumed to occur between days 20 and 24 of a regular menstrual 
cycle [2, 5] (Figure 1). The cyclic fluctuations of the endometrium are coordinated 
by the ovarian hormones estrogen (E2) and progesterone (P4); a finely balanced 
signaling process mediated by these hormones defines the WOI. The menstrual 
cycle is divided in two phases: proliferative or follicular, and secretory or luteal 
[6]. During the proliferative phase (PP), E2 from the maturing follicle allows the 
elongation of the spiral arteries and the proliferation of endometrial stromal cells 
(EnSCs) and glands [7]. Afterwards, during the secretory phase (SP), P4 from the 
corpus luteum induces secretory changes; the endometrium thickens and it acquires 
a receptive phenotype that will support blastocyst attachment [8–10]. During the 
Mid-Secretory Phase (MSP) circulating P4 induces EnSCs to undergo decidualiza-
tion [11]. Decidualization is the transformation of the endometrial stroma into a 
dense cellular matrix known as the decidua, this process initiates during the SP 
in the stroma and, if pregnancy occurs, it progresses into the development of the 
decidua which will in turn form the maternal placenta [12]. The optimization of 
the endometrium to support embryo implantation is a complex and multifactorial 
process that involves morphological, biochemical, and genetic changes [13]. ER is a 
key aspect that affects implantation rates in IVF procedures considering that a pre-
cise embryo-endometrial synchrony is completely necessary to achieve a successful 
pregnancy [4, 14]. Thus, understanding the molecular mechanisms behind ER will 
facilitate the optimization and improvement of infertility treatments.
2. Factors involved in endometrial receptivity
2.1 Evaluation of endometrial morphology for receptivity assessment
Morphological changes during the endometrial cycle generate markers that have 
been used over decades to assess receptivity, such as histological evaluation of a biopsy 
and ultrasound examination of the endometrium. Endometrial biopsies are now 
Figure 1. 
Endometrial dynamics throughout the menstrual cycle. This picture was modified from Servier Medical Art 
under the Creative Commons License 2018.
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considered to provide little clinically relevant information [15, 16]. Additionally, the 
formation of pinopodes was thought to show potential as a clinical marker to assess 
ER [17]. However, the presence of pinopodes was demonstrated not only during the 
WOI but also in the post-receptive endometrium, precluding in this way its use as 
a marker of ER [17, 18]. On the other hand, ultrasound examination is a routinely 
used technique in IVF procedures [9, 19]. This non-invasive technique is based on the 
interpretation of a medical ultrasound of the endometrium. Various ultrasonographic 
parameters have been proposed as pregnancy predictors, such as endometrial thick-
ness, volume, and blood flow patterns. The most commonly used is endometrial thick-
ness [20, 21]. Due to differences in stimulation protocols, sonographic approaches, 
and difficulties in obtaining a standard sagittal view of the uterus, discrepancies in 
the cut-off value of endometrial thickness to achieve pregnancy arise [22]. Generally, 
it is considered that a minimum of 6–8 mm in endometrial thickness is necessary for 
a successful pregnancy [23–25]. Nevertheless, case reports have described pregnancy 
establishment despite an endometrial thickness of no more than 4 mm [26, 27]. Three-
dimensional (3D) sonography assesses ER by considering endometrial thickness, 
volume, and angiogenic dynamics. The endometrial volume of fewer than 2 ml has 
been shown to decrease pregnancy rates significantly [19, 28, 29]. Another evaluated 
criterion is an endometrial pattern, which can be classified as triple-line, intermediate, 
or homogenous [30]. Among these, the triple-line pattern has been suggested to reflect 
ER [24, 31] broadly. Finally, the impact of ovarian stimulation on ER has yet to be 
determined. Abnormal hormone concentrations the due to stimulation protocols dur-
ing IVF might affect endometrial morphology and thereby ER [32]. Comprehensively, 
although morphological elements are important components of receptivity, there is 
still no consensus on the extent in which they can be used as WOI predictors.
2.2 Genetic factors involved in ER
Endometrial genetic abnormalities can lead to implantation failure due to dys-
regulation of critical processes such as trophoblast invasion and angiogenesis. Here, 
we discuss common genetic abnormalities that have been analyzed to determine 
their role in implantation failure (Table 1). Parental chromosomal abnormalities 
such as mutations and translocations should be considered relevant in the efficacy 
of improving reproductive outcome.
2.2.1  Angiogenetic factors: vascular endothelial growth factor (VEGF), endothelial 
nitric oxide synthase (eNOS), TP53 tumor suppressor (TP53), murine double 
minute 2 (MDM2), herpes virus-associated ubiquitin-specific protease 
(HAUSP)
Successful pregnancy is dependent on adequate placental circulation and fetal 
vasculature. The development of a normal vascular network during implantation, 
embryo development, and placentation requires cooperation between different cell 
types and various growth factors. VEGF is a potent angiogenic factor that plays an 
essential role in embryo implantation/development. Four VEGF polymorphisms 
have been reported to affect VEGF activity and expression increasing aberrations 
in vascular formation and/or function. The polymorphism −1154G/A located in the 
promoter region has been associated with RPL [33], RSA [34, 35], and RIF [36, 37]. 
Moreover, a meta-analysis showed that genotypes −2578C/A, −634G/C, and 936C/T 
increase the risk of RSA as well [38]. Furthermore, eNOS, which is expressed in the 
terminal chorionic villous vessels, is important for vascular nitric oxide (NO) pro-
duction to supply nutrients to the fetus. Only the eNOS Glu298Asp polymorphism 
has been shown to be significantly associated with RPL [39]. Additionally, success-
ful trophoblast invasion requires the induction of paracrine apoptotic reactions to 
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considered to provide little clinically relevant information [15, 16]. Additionally, the 
formation of pinopodes was thought to show potential as a clinical marker to assess 
ER [17]. However, the presence of pinopodes was demonstrated not only during the 
WOI but also in the post-receptive endometrium, precluding in this way its use as 
a marker of ER [17, 18]. On the other hand, ultrasound examination is a routinely 
used technique in IVF procedures [9, 19]. This non-invasive technique is based on the 
interpretation of a medical ultrasound of the endometrium. Various ultrasonographic 
parameters have been proposed as pregnancy predictors, such as endometrial thick-
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of improving reproductive outcome.
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Successful pregnancy is dependent on adequate placental circulation and fetal 
vasculature. The development of a normal vascular network during implantation, 
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essential role in embryo implantation/development. Four VEGF polymorphisms 
have been reported to affect VEGF activity and expression increasing aberrations 
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promoter region has been associated with RPL [33], RSA [34, 35], and RIF [36, 37]. 
Moreover, a meta-analysis showed that genotypes −2578C/A, −634G/C, and 936C/T 
increase the risk of RSA as well [38]. Furthermore, eNOS, which is expressed in the 
terminal chorionic villous vessels, is important for vascular nitric oxide (NO) pro-
duction to supply nutrients to the fetus. Only the eNOS Glu298Asp polymorphism 
has been shown to be significantly associated with RPL [39]. Additionally, success-
ful trophoblast invasion requires the induction of paracrine apoptotic reactions to 
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Gene Polymorphism rs code Relevance References
APOE Heterozygous genotype is more frequent 
in women with RPL
[33]
eNOS VNTR (B/A) Association to the risk of RPL [77]
No associated [78]
Glu298Asp Homozygote genotype T/T is associated 
with risk of IRM
[39]
ESR1 IVS1-397T>C rs2234693 Related to unknown thin endometrium in 




F2 G20210A rs1799963 No association [58, 60, 62, 
63]
Heterozygous genotype is more frequent 
in women with RSA in the first trimester 
[57] and women with RPL [42]
[42, 57]
F5 G1691A, Leiden rs6025 No association [57, 58, 62, 
63]
More frequent in women with RIF [60]
H1299R (R2) No association [58, 62, 63]
Y1702C No association [58, 62, 63]
F8 V34L More prevalent in women with RPL [42, 58]
No association [62, 63]
FGB G-455A rs1800790 No association [57, 58, 62, 
63]
GPIIIa C1565T No association [57]
HAUSP rs1529916 G/A rs1529916 Allele A is associated with RIF [40]
HPA1 HPA1 a/b  
(L33P)
No association [58, 62, 63]
LIF C715A No associated [72]
G3400A More frequent in nulligravid women [72, 73]
G3424A No associated [72]
T1414G rs929271 G/G genotype is associated with RIF [40, 74]
MDM2 T309G rs2279744 Allele G is associated with RIF [40]
MTHFR A1298C rs1801131 No association [58, 62–64]
C677T rs1801133 More frequent in women with 
unexplained infertility [64], RPL [42, 
58], and RSA [60]
[42, 58–60]
No association [57, 62, 63]
MUC1 VNTR Women with unexplained infertility 
might have susceptibility to 
implantation failure due to small MUC1 
allele size
[67]
No association [68, 69]
MUC4 VNTR No association [70]
PAI-1 4G/5G rs1799889 More prevalent in women with RIF [63] 
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secrete proteases capable of digesting the endometrial extracellular matrix (ECM) 
[36]. TP53 is a potent regulator of apoptosis, cell cycle, angiogenesis, and embry-
onic development. A TP53 polymorphism at codon 72, encoding either proline or 
arginine, was reported to alter the TP53 activity and affect human fertility [40]. 
The Arg72 variant has been shown to induce higher apoptotic activity than Pro72. 
Therefore, Pro72 variant might cause inadequate trophoblast invasion, increasing 
the risk of RPL [41] and RIF [37, 40]. In this manner, women with Pro/Pro genotype 
have a higher risk of RPL than women with the Arg/Arg or Arg/Pro genotypes. 
Following, MDM2 and HAUSP regulate TP53. MDM2 binds to TP53 to degrade it 
through poly-ubiquitination, blocking its ability to function as a transcription factor. 
The MDM2 SNP309 is a functional SNP that increases MDM2 expression levels and 
attenuates TP53 pathway. HAUSP, on the other hand, acts as a specific deubiquitinase 
for TP53, the A allele has a significant association with infertility in young patients 
(<35 years) but not in the older patients, similarly to the MDM2 SNP309 G allele. 
Those observations suggest that MDM2 and HAUSP may be involved in the regula-
tion of human fertility through the regulation of TP53 [40].
Gene Polymorphism rs code Relevance References
PR H770H-C/T No association [54]
G/T—Val660Leu rs1042838 More prevalent in women with 
unexplained infertility
[65]
V660L No association [54]
PT53 Codon 72 Pro rs1042522 Homozygote genotype is associated with 
RPL [41, 75], IRM [76] and RIF [37, 40]
[37, 40, 41, 
75, 76]
Codon 72 Arg rs1042522 Homozygote genotype is associated with 
RIF
[75]
PTGS2 G-765C rs20417 Association with implantation failure 
susceptibility
[55]
TFF3 rs225361 A/G rs11701143 Homozygous genotype is associated 
with less live births before their first 
spontaneous abortion
[61]
rs225361 A/G rs11701143 No association [66]
rs11701143 T/C rs225361 Associated with idiopathic RSA [61]
rs11701143 T/C rs225361 No association [66]
rs225439 G/A rs225439 No association [61, 66]
ros533093 C/T rs533093 No association [61, 66]
rs77436142 G/C rs7743614 No association [61, 66]
VEGF G-1154A rs1570360 Homozygote A/A genotype associated 




C-2578A rs699947 No associated [34]
G-634C rs2010963 No associated [34]
C936T rs3025039 No associated [34]
Probably implicated mutations in implantation failure, studies are listed even when no association was found, rs code 
is mentioned whenever it is reported.
Table 1. 
Genetic abnormalities involved in implantation failure.
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secrete proteases capable of digesting the endometrial extracellular matrix (ECM) 
[36]. TP53 is a potent regulator of apoptosis, cell cycle, angiogenesis, and embry-
onic development. A TP53 polymorphism at codon 72, encoding either proline or 
arginine, was reported to alter the TP53 activity and affect human fertility [40]. 
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tion of human fertility through the regulation of TP53 [40].
Gene Polymorphism rs code Relevance References
PR H770H-C/T No association [54]
G/T—Val660Leu rs1042838 More prevalent in women with 
unexplained infertility
[65]
V660L No association [54]
PT53 Codon 72 Pro rs1042522 Homozygote genotype is associated with 
RPL [41, 75], IRM [76] and RIF [37, 40]
[37, 40, 41, 
75, 76]
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RIF
[75]
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susceptibility
[55]
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[61]
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rs225439 G/A rs225439 No association [61, 66]
ros533093 C/T rs533093 No association [61, 66]
rs77436142 G/C rs7743614 No association [61, 66]
VEGF G-1154A rs1570360 Homozygote A/A genotype associated 




C-2578A rs699947 No associated [34]
G-634C rs2010963 No associated [34]
C936T rs3025039 No associated [34]
Probably implicated mutations in implantation failure, studies are listed even when no association was found, rs code 
is mentioned whenever it is reported.
Table 1. 
Genetic abnormalities involved in implantation failure.
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2.2.2 Apolipoprotein E (APOE)
Due to the increase in total cholesterol levels during pregnancy, APOE plays a 
crucial role in lipid metabolism. APOE has three alleles in the long arm of chromo-
some 19 at position 13.2: ε2, ε3, and ε4. Individuals harboring the allele ε4 have 
higher cholesterol levels than the ones carrying the ε3/ε3 allele, whereas levels in 
those with the ε2 allele are lower [42].
2.2.3 Estrogen receptor α (ESR1)
ESR1 is a ligand-activated transcription factor essential for sexual development 
and reproductive function; its dysregulation leads to the development of various 
diseases such as cancer, cardiovascular disease, and inflammation, among others [43]. 
Due to alternative splicing of mRNA, it possesses three isoforms: ERαΔ3, ERα36, and 
ERα46 [43]; in a study performed by Yuan and Le [44], the polymorphisms rs2234693 
and rs9340799 were related to the uncommonly thin endometrium.
2.2.4 Leukemia inhibitor factor (LIF)
LIF is an important implantation factor that promotes proliferation, invasion, 
and differentiation; its expression is regulated by the transcription factor tumor 
protein TP53 (TP53). Few studies have found a correlation between LIF gene 
polymorphism and reproductive capacity, Kang et al. demonstrated that SNP in the 
3’UTR of the LIF (rs929271) gene is associated with infertility [40].
2.2.5 Mucin 1 (MUC1), Mucin 4 (MUC4)
MUC1 is an anti-adhesion molecule secreted by human endometrial epithelium, 
it has been suggested that its expression prevents the adherence of blastocyst to the 
endometrium. Interestingly, MUC1 must be locally removed in a paracrine fashion 
at the implantation site during the WOI to allow contact between the embryo and 
the endometrium, making it an important factor in determining ER [45–48]. MUC1 
is a highly polymorphic gene that differs in the size of the region carrying the 
O-glycosylation sites: the variable number tandem repeat region (VNTR), which 
can go from 20 to 125 repeats [49]. Similarly, MUC4 is a greatly expressed mucin in 
endometrial epithelium [50], its gene is highly polymorphic and it contains a VNTR 
region that can go from 145 to 395 repeats [51]. Although its role in human infertil-
ity has not been fully explored, studies in other species have suggested that it plays a 
role in embryo implantation [52, 53].
2.2.6 Progesterone receptor (PR)
The PROGINS complex are three mutations in the PR gene that may be associ-
ated with unexplained infertility and implantation failure: a 306 bp insert in intron 
G of the dT2 allele in PR, the mutated alleleV660L, and guanine to thymine substi-
tution in exon 4, resulting in a valine to leucine change in the hinge region of PR, 
and a cytosine to thymine substitution at exon 5 [54].
2.2.7 Prostaglandin-endoperoxide synthase 2 (PTGS2)
PTGS2 is a key enzyme involved in the conversion of arachidonic acid to prostaglan-
dins (PGs). The −765G>C SNP mutation in the promoter region of PTGS2 upstream 
the transcriptional start site in the putative Sp1 site can cause alterations in Sp1 binding 
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[55]. Accordingly, the hypermethylation of the NF-IL6 site within the PTGS2 promoter 
results in elevated gene expression in eutopic endometrium in endometriosis [56].
2.2.8  Thrombolytic factors: coagulation factor II (F2), coagulation factor V (F5), 
coagulation factor XIII a chain (F13A1), methylenetetrahydrofolate reductase 
(MTHFR), plasminogen activator inhibitor-1 (PAI-1)
Thrombophilia, the predisposition for thrombosis, has been shown to be a 
risk factor for successful pregnancy due to impaired vascularization at the time 
of implantation. Therefore, the possible association between early pregnancy loss 
and polymorphisms at coagulation factors and thrombolytic genes responsible for 
inherited or acquired thrombophilia has been investigated. The coagulation factor 
II SNP G20210A in the 3′-untranslated region of F2 causes elevated prothrombin in 
plasma, leading to enhanced blood coagulation [57]. Furthermore, factor V Leiden 
mutation, G1691A, is a single nucleotide substitution in the F5 gene that results in 
reduced clearance of factor Va due to its blocked inactivation by activated protein C, 
increasing the risk of thrombosis [42, 57]. Also, factor XIII V34L polymorphism is a 
guanine to thymine substitution in exon 2 of F13A1 that leads to a valine for leucine 
change in residue 34; this SNP leads to reduced susceptibility to fibrinolysis and 
influences fibrin degradation [57]. Moreover, MTHFR is the rate-limiting enzyme in 
the methyl cycle. C677T polymorphism causes a substitution of valine for alanine, 
resulting in a thermolabile variant of the enzyme with reduced catalytic activity; 
combined with the SNP AC1298C, it is associated with hyper-homocysteinemia, a 
risk factor for venous and arterial thrombosis [42, 58–60]. Additionally, PAI-1 is a 
key regulatory element in the fibrinolysis cascade, it is believed to control proteolysis 
and remodeling of maternal tissue during trophoblast invasion. The 4G/5G poly-
morphism is located 657 bp upstream from the start site of transcription within the 
PAI-1 promoter and results in an allele with decreased transcriptional activity [42].
2.2.9 Trefoil factor 3 (TFF3)
TFF3 is a mucin-associated peptide co-expressed in mucus cells that acts as a 
mitogen to promote epithelial cell migrations and mediates epithelial repair after 
damage. The SNP rs11701143 is located in the promoter region of TFF3 within the 
regulatory region of the transcription binding site, whereas rs225361 is an intron 
variant located within a regulatory region. The exact function of both SNPs remains 
to be elucidated [61].
2.3 Immunological factors contributing to ER
The immune system plays a major role in the process of implantation and preg-
nancy maintenance [62]. During decidualization, endocrine processes transform 
uterine fibroblasts into cells that can produce hormones, growth factors, and matrix 
components to support embryo implantation [63, 64]. Furthermore, tolerance of 
the immune maternal system is required in pregnancy to avoid rejection of the semi-
allograft or allograft embryo and for its successful implantation [65]. The decidua 
is a privileged site for immune tolerance; a large number of molecules and immune 
cell types participate in this process, leukocytes, macrophages, T lymphocytes, and 
dendritic cells comprise around 30 to 40% of the cells within the decidual stroma in 
early pregnancy. Among leukocytes, uterine natural killer (uNK) cells are activated 
and they significantly increase during decidualization (65–70%) [66, 67]. Increases 
in uNK cells denote three main functions in the endometrium: regulation of placental 
and trophoblast growth by cytokines [68, 69], local immunomodulation [70, 71], and 
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control of trophoblast invasion [69]. Furthermore, trophoblast cells play a major role 
in immune tolerance since these cells do not express major histocompatibility complex 
(MHC) class I (HLA-A and HLA-B) or class II molecules; ensuring that maternal T cells 
with αβ receptors cannot mount a classic cytotoxic attack against fetal paternal alloan-
tigens. The trophoblast also protects itself by expressing Fas ligand (Fas L), which is 
important in the elimination of maternal reactive T cells by apoptosis induction [72–74]. 
Other important component of this process is T-regulatory (Treg) cells; these cells are 
essential for immunosuppression, prevention of autoimmunity, and maternal tolerance 
to the fetus [75–78]. Treg cells have been shown to be locally enriched in decidua during 
early normal pregnancy [79]. Furthermore, Forkhead box P3 (Foxp3) is a master regu-
lator of Treg cell development, function, and differentiation [80]. Expression of FOXP3 
was reduced approximately two-fold in endometrial biopsies of infertile women, impli-
cating that the impaired differentiation of uterine T-cells into the Treg phenotype is a 
key determinant of fertility [81, 82]. On the other hand, helper T cells (CD4+) facilitate 
embryo implantation by regulating endometrial differentiation; they secrete inter-
leukins and interferons that establish the implantation microenvironment. Successful 
pregnancy is dependent upon Th1/Th2 balance [83]. While Th1 cytokines are harmful 
for pregnancy, Th2 cytokines favor fetal growth and regulate uterine expression of 
fatty acid amide hydrolase (FAAH), LIF, and trophoblast release of human chorionic 
gonadotropin (hCG), which are known to play important roles during implantation 
[84–86]. Piccinni et al. demonstrated that T cells from decidua of women with a miscar-
riage show predominantly Th1-type cytokines with decreased Th2-type [84, 87, 88]. 
Finally, P4 and E2 mediate the downregulation of the maternal immune system [89]. P4 
stimulates decidual proliferation; therefore, pregnancy results in an upregulation of P4 
receptors on activated lymphocytes among placental cells and decidual CD56+ cells. In 
the presence of sufficient P4, these cells express progesterone-induced blocking factor 
(PIBF), a mediator that exerts substantial anti-abortive activities.
2.4 Biochemical markers involved in ER
We review molecular markers involved in the decidualization process that could 
be suitable as makers to assess ER.
2.4.1 Homeobox A10 (HOXA10)
HOXA10 is a transcription factor member of the homeobox family, known to be 
involved in the genetic control of embryonic development and in the regulation of 
the adult female reproductive tract [12, 90]. HOXA10 regulates downstream target 
genes that lead to endometrium development and receptivity acquisition [91], such as 
insulin-like growth factor binding protein 1 (IGFBP1) [12, 92, 93], genes of the Wnt 
pathway (reviewed by Sonderegger et al. [94], integrin β3 (ITGB3) [12, 90, 92], and 
empty spiracles homolog 2 (EMX2) [12, 95]. HOXA10 is regulated by P4 in a dose-
dependent manner [12, 90, 91]. The expression of HOXA10 is low during the PP and 
it rapidly increases in the MSP [12, 90]. The diminished expression of HOXA10 in 
endometria of women with recurrent pregnancy loss (RPL) [96], adenomyosis [97], 
endometriosis [92], polycystic ovary syndrome (PCOS) [98], and idiopathic infertil-
ity [99] indicates that this gene could be essential for fertility [12].
2.4.2 Heparin-binding epidermal growth factor-like growth factor (HB-EGF)
HB-EGF is a member of the epidermal growth factor (EGF) family, it is 
expressed in the human uterus at the time of implantation and its expression is 
under steroidal hormone control [100–103]. The transmembrane form is associated 
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with cell adhesion and migration, it allows communication with the blastocyst by 
acting as a chemoattractant [101, 104]. HB-EGF expression is low in the PP and 
increases in the ESP immediately prior to the WOI, after which its levels decrease 
[101–103, 105]. Also, mRNA levels are low in pregnant endometrium and high in 
placental tissues at an early stage of development, suggesting that the HB-EGF 
ligand not only potentiates the health and survival of the peri-implantation 
embryo, but also induces the progression of its development [104]. HB-EGF stimu-
lates epithelial expression of key endometrial proteins that are important biomark-
ers of the WOI, including LIF, HOXA10, and ITGB3 [100].
2.4.3 Leukemia inhibitory factor (LIF)
LIF is a member of a cytokine family with functional redundancy that includes 
interleukin 6 (IL6), oncostatin (OSM), ciliary neurotrophic factor (CNTF), and 
cardiotrophin 1 (CT1). They regulate proliferation, differentiation, and cell sur-
vival in different cellular systems [106]. LIF acts on cells by binding to the heterodi-
meric LIF receptor (LIFR), which consists of two transmembrane proteins, LIFR 
and glycoprotein 130 (gp130). LIFR activates several signaling pathways including 
the JAK/STAT, MAPK, and P13-kinase pathways, whereas gp130 participates in the 
activation of STAT1, STAT3, and STAT5B [107]. LIF induces the expression of cyto-
kines and other regulatory molecules that could serve to regulate preimplantation 
development and embryo implantation [106–108]. LIF is one of the most important 
cytokines for receptivity during the WOI, the expression of LIF and LIFR reaches 
its highest level during the WOI in the MSP, LSP, and in early pregnancy in both 
surface and glandular epithelial cells under the influence of P4 [106, 107, 109, 110]. 
LIF can also be detected in decidual leukocytes, which are abundant at the implan-
tation site; interestingly, LIF expression is low in women with unexplained infertil-
ity [106, 107, 111]. LIF also plays a crucial role in the regulation of fetal-maternal 
interactions during pregnancy, this cytokine mediates uterine receptivity through 
autocrine/paracrine interactions by binding to LIFR on the luminal epithelium to 
permit blastocyst attachment [106], but also regulates trophoblast function and 
vascular formation in the placenta [109].
2.4.4 Integrin β3 (ITGB3)
Integrins are ubiquitous cell adhesion molecules involved in maintaining nor-
mal tissue morphology and participate in cell–cell and cell-substrate interactions 
[100, 110, 112, 113]. In the human endometrium, integrins are involved in early 
embryo-endometrial interactions [90]. ITGB3 subunit is present after the ESP 
and its expression extend into the pregnancy [112, 114]. It has been reported that 
healthy fertile women show higher ITGB3 expression than patients with unexplained 
infertility [46, 96, 113–115]. Moreover, its dysregulation appears to characterize two 
distinct pathophysiological conditions that involve distinct mechanisms of defective 
ER: Type I and Type II. Type I defect is an out-of-phase endometrium with negative 
ITGB3 subunit expression, portrays a shifted WOI, and hormonal inadequacy or 
responsiveness is implicated, on the other hand, Type II defect is an “in-phase” endo-
metrium with negative ITGB3 subunit expression and connotes the complete loss of 
the WOI. Furthermore, ITGB3 is expressed in EnSCs and endometrial glands with 
the highest levels in the MSP to LSP, suggesting a role in the regulation of endome-
trial function and implantation [115, 116]. Due to its temporal distribution and the 
effects of implantation when it is not present, ITGB3 is a useful molecular marker to 
assess ER. ITGB3 is regulated in the endometrium through a molecular mechanism 
via sex steroid signaling where HOXA10 acts as an intermediary [90, 96].
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tation site; interestingly, LIF expression is low in women with unexplained infertil-
ity [106, 107, 111]. LIF also plays a crucial role in the regulation of fetal-maternal 
interactions during pregnancy, this cytokine mediates uterine receptivity through 
autocrine/paracrine interactions by binding to LIFR on the luminal epithelium to 
permit blastocyst attachment [106], but also regulates trophoblast function and 
vascular formation in the placenta [109].
2.4.4 Integrin β3 (ITGB3)
Integrins are ubiquitous cell adhesion molecules involved in maintaining nor-
mal tissue morphology and participate in cell–cell and cell-substrate interactions 
[100, 110, 112, 113]. In the human endometrium, integrins are involved in early 
embryo-endometrial interactions [90]. ITGB3 subunit is present after the ESP 
and its expression extend into the pregnancy [112, 114]. It has been reported that 
healthy fertile women show higher ITGB3 expression than patients with unexplained 
infertility [46, 96, 113–115]. Moreover, its dysregulation appears to characterize two 
distinct pathophysiological conditions that involve distinct mechanisms of defective 
ER: Type I and Type II. Type I defect is an out-of-phase endometrium with negative 
ITGB3 subunit expression, portrays a shifted WOI, and hormonal inadequacy or 
responsiveness is implicated, on the other hand, Type II defect is an “in-phase” endo-
metrium with negative ITGB3 subunit expression and connotes the complete loss of 
the WOI. Furthermore, ITGB3 is expressed in EnSCs and endometrial glands with 
the highest levels in the MSP to LSP, suggesting a role in the regulation of endome-
trial function and implantation [115, 116]. Due to its temporal distribution and the 
effects of implantation when it is not present, ITGB3 is a useful molecular marker to 
assess ER. ITGB3 is regulated in the endometrium through a molecular mechanism 
via sex steroid signaling where HOXA10 acts as an intermediary [90, 96].
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Other identified markers that are important for decidualization in the human endo-
metrium include PR, particularly its encoded isoform progesterone receptor A (PR-A), 
homeobox A11 (HOXA11), PTGS2, MUC1, and interleukin 11 receptor (IL11R) [12].
2.5 Transcriptomic signature to determine the WOI
Microarray technology has been widely used to determine the transcriptomic 
profile of the endometrium by analyzing the expression of large batches of genes at 
different stages of the menstrual cycle. The most representative and commercially 
available test in this regard is perhaps the Endometrial Receptivity Array (ERA), 
developed in 2009 by Diaz-Gimeno et al., this test identifies the unique transcrip-
tomic signature of the receptive endometrium by analyzing 238 differentially 
expressed genes, predicting the WOI for personalized embryo transfer (pET) [108]. 
Various research groups have analyzed changes in gene expression during the differ-
ent phases of the endometrial cycle using microarray-based technologies [117–120], 
however, due to differences on results, unanimity about the main genes to be analyzed 
to determine the WOI has not been reached. Factors that contribute to the disagree-
ment among studies results include differences on experimental design, utilized 
probes, sample acquisition day, sample size, collection method, and the application 
of distinct statistical analyses. Nevertheless, some genes have been reported to be 
expressed similarly in more than one work, here, we present a compilation of the 
expression profiles of those candidate genes in the human endometrium (Table 2).
2.6 miRNAs involved in ER
Micro-RNAs (miRNAs) are small, single-stranded, non-protein-coding RNA 
sequences of ~18–25 nucleotides in length that play an important post-transcrip-
tional regulatory role in gene expression [121, 122] by targeting mRNAs for cleavage 
or transcriptional repression [123]. More than two decades have passed since the 
initial discovery of miRNAs in Caenorhabditis elegans by Lee et al. [124]; since then, 
great progress has been made in the understanding of miRNAs: what they are, 
how are synthesized, how regulate gene expression, and how they are involved in 
the formation and progression of pathological disorders. Extracellular miRNAs 
have been ubiquitously detected in body fluids [125]. Therefore, the presence and 
stability of miRNAs in biological fluids have advocated their potential as non-
invasive biomarkers. Nevertheless, the identification of reliable miRNA biomarkers 
with reproducible profiles has been a challenge, and their diagnostic promise has 
remained a work in progress since they have still not entered the clinical field [126]. 
Nonetheless, given that miRNAs are differentially expressed in the endometrium 
across the menstrual cycle [127–131], several studies have been conducted to 
explore their role in ER [131–136]. Table 3 presents a summary of these studies.
2.7 The endometrial secretome as a potential tool to ascertain ER
The aim to develop alternative non-invasive strategies to provide accurate 
receptivity assessment has drawn assiduity to the endometrial secretome, which is 
based in the identification of factors secreted by cells or tissues at a particular time 
in either physiological states or pathological conditions [137], including proteins, 
lipids, and metabolites. Therefore, the analysis of differentially present molecules 
in the uterine cavity at different time points of the menstrual cycle could potentially 
help to identify the WOI and to diagnose uterine pathologies. Sample collection of 
endometrial fluid (EF) collection in the peri-implantation period is an easy pro-
cedure performed with minimally invasive tools that could easily be implemented 
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Expression profiles of genes involved in ER.
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in ART procedures. Proteomics of EF has already rendered valuable information 
regarding ER; Casado-Vela et al. identified 803 proteins in EF aspirates using three 
different proteomic strategies [138]. Additionally, Boomsma et al. [139] analyzed 
endometrial secretions prior to embryo transfer from 210 women undergoing IVF 
to determine differences in cytokine profiling at the time of implantation, finding a 
negative and a positive association of monocyte chemo-attractant protein-1 (MCP-1) 
and IFN-γ-inducible 10 kDa protein (IP-10) levels and implantation, respectively. 
Lipidomics, on the other hand, seems to have rendered slight information on 
receptivity [140], nevertheless, a study performed by Berlanga et al. [141] and fol-
lowed by Vilella et al. [142, 143] carried out lipidomic analyses of EF from patients 
at different stages of their menstrual cycle, they determined a significant increase in 
Prostaglandin E2 (PGE2) and Prostaglandin F2α (PGF2α) between days 19 and 21, 
coincident with the WOI. In a recent study performed by Durairaj, Aberkane et al. 
[144], the contribution of EnSCs to failed implantation was examined by analyzing 
the secretome profile of EnSCs cultures in-vitro. From there, they encountered that 
secretome profiles of pregnant women are less divergent in implantation-positive-
cultures particularly in Day 0 (undifferentiated cells), suggesting that endometrial 
defects linked to reproductive failure could be more prominent in the PP, a phase 
that is commonly thought to be not relevant for ER studies. This research group also 
demonstrated that the secretome of undifferentiated EnSCs compromises blastocyst 
development. Finally, they determined that a deficiency of endometrial mesenchy-
mal stem-like cells (MSCs) could lead to aberrant EnSC function and implantation 
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With a 2-fold threshold: 105 
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expressed: 93 ↑ and 12 ↓.
After raw signal value 
correction, 15 were found to 
be significantly different. 10 
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125b-5p, 21-5p] and 5 ↓ 
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mesenchymal transition, 
and miRNA tumor 
suppressors. Network 
regulatory analysis: 176 
miRNA-mRNA interactions. 
The top core mRNA 
were ABP1, AQP3, ASS1, 
and TIMP3, the top core 
miRNAs were has-miR-
4668-5p, 429, and 5088
Studies conducted to analyze miRNA expression profiles during the menstrual cycle as potential biomarkers of the 
WOI. A summary of the differentially expressed miRNAs and predicted targets found in recent studies is presented. Its 
relevance regarding the role of miRNAs is also addressed.
Table 3. 
Studies of miRNA-profiling during the WOI.
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the endometrium that supports the acquisition of receptivity and raises the prospect 
of screening the endometrium before the initiation of an ART procedure.
2.8 The microbiome as a novel aspect of ER
Historically, the uterus was assumed to be free of bacteria as the fetal envi-
ronment was considered to be physiologically sterile [145], this notion implies 
that the neonate’s microbiome is acquired only during and after birth. Although 
recent research still supports this conception [146], others have characterized 
upper genital tract microbiota [147–150], suggesting that the endometrial and 
vaginal microbiota not be identical [151]. What is more, the study by Moreno et al. 
[147, 152], which defined the microbiota in the EF as Lactobacillus-dominated (LD) 
or non-Lactobacillus-dominated (NLD), suggested that the presence of an NLD 
microbiota in a receptive endometrium was associated with a significant decrease 
in implantation, pregnancy, ongoing pregnancy, and live birth rates. Nevertheless, 
they acknowledge that in the absence of pathological signs, an NLD microbiota 
could be considered normal since Lactobacillus-deficient communities have been 
identified in the genital tract of otherwise healthy asymptomatic women [153]. This 
conception sets the stage for further research of the human microbiome, expands 
the possibilities to assess individualized receptivity based on the endometrial 
microbiome, and opens the door to explore targeted therapies for an altered endo-
metrial microbial habitat.
3. Remarks
This review encloses different aspects of ER, spotlighting the opening of the 
WOI. Altogether, this compilation could aid in the development of new clinical 
practices that define an individual’s receptive window for pET to improve ART 
results ultimately.
Nowadays, ER is the rate-limiting step in successful ART procedures that end 
up in pregnancy and child delivery. The endometrial tissue is a ponderous element 
in fertility; it constitutes the soil in which a viable embryo will implant to achieve 
progeny. The attainment of ER involves an extensive assortment of genetic and 
biochemical mechanisms that must integrate in a parallel manner. Understanding 
of this process as an entity is still insufficient; nevertheless, the surge of new 
technologies is contributing in the deciphering of receptivity mechanisms and in 
search of novel biomarkers that could serve to detect the WOI. Notably, although 
most studies focus on individual genetic mutations, a more comprehensive view of 
the parental genetics is needed to determine whether an endometrium is adequate 
for embryo transfer before the initiation of an ART procedure. Due to ambiguous 
or non-conclusive results in search of genetic predispositions of endometrial-
associated infertility, it would be controversial to provide genetic counseling 
currently. Perhaps, in the future, massive sequencing could help to provide insights 
into the importance of single and multiple genetic mutations to establish a receptive 
or non-receptive profile. If assertive, this profile could be applied as an endometrial 
pre-implantation parental test to improve the rates of healthy pregnancies and live 
births. With this in mind, in our opinion, the best short-term approaches towards 
detecting or improving ER are the transcriptome, microbiome, and miRNA signa-
tures, all achievable using the power of NGS. This review encloses different aspects 
of ER, spotlighting the opening of the WOI. Altogether, this compilation could aid 
in the development of new clinical practices that define an individual’s receptive 
window for pET to improve ART results ultimately.
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Abstract
Aneuploidy, the hold of an abnormal number of chromosomes that differs from
the normal karyotype, is a recognized leading cause of miscarriage and congenital
disabilities. In human gametes and embryos, aneuploidy rates are prevalent, and
these rates increase with advanced maternal age; additionally, it has been suggested
that hormonal stimulation for achieving in vitro fertilization (IVF) protocols further
increases aneuploidy rates. Although about 65% of chromosomally abnormal
embryos culminate in spontaneous miscarriages, there is still evidence of live births
harboring crucial aneuploidies. Furthermore, although some frequent aneuploidies
are consistent, others differ between countries, making it harder to focus on a
specific set of anomalies but vital to focus regionally on those more prevalent.
Preimplantation genetic testing (PGT) is a highly endorsed technique in assisted
reproductive treatments to evaluate possible embryo aneuploidies, genetic defects,
and congenital disorders. On this subject, this study shows that IVF aneuploidy
rates in embryo cohorts of high morphological quality are inversely associated with
implantation rates. In its entirety, this study reinforces the utility of PGT for
embryo evaluation.
Keywords: aneuploidy, preimplantation genetic testing, embryo implantation,
in vitro fertilization, karyotype
1. Introduction
Aneuploidy is defined as a chromosome number that is not an exact multiple of
the usually haploid number [1]. The terms haploid and diploid that describe single
(n) and double (2n) chromosome sets in cells originate from the Greek terms
haplóos meaning single and diplóos meaning double. The term ploidy was subse-
quently derived to describe the total chromosome content of cells. Consequently,
the term euploid refers to a chromosome with an exact multiple of the haploid
number [2]. Human body cells (somatic cells) are diploid, carrying two complete
sets of chromosomes: one set of 23 chromosomes from their father and one set of 23
chromosomes from their mother; the two sets combined provide a full complement
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that hormonal stimulation for achieving in vitro fertilization (IVF) protocols further
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1. Introduction
Aneuploidy is defined as a chromosome number that is not an exact multiple of
the usually haploid number [1]. The terms haploid and diploid that describe single
(n) and double (2n) chromosome sets in cells originate from the Greek terms
haplóos meaning single and diplóos meaning double. The term ploidy was subse-
quently derived to describe the total chromosome content of cells. Consequently,
the term euploid refers to a chromosome with an exact multiple of the haploid
number [2]. Human body cells (somatic cells) are diploid, carrying two complete
sets of chromosomes: one set of 23 chromosomes from their father and one set of 23
chromosomes from their mother; the two sets combined provide a full complement
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of 46 chromosomes. Human gametes (or sex cells), sperm and oocytes, are haploid
and contain only one set of 23 chromosomes.
Aneuploidies can occur either by chromosome gains (trisomies) and losses
(monosomies) due to chromosome segregation errors, the so-called “whole chro-
mosomal” aneuploidy or due to rearrangements of chromosomal parts, often
accompanied by deletions, amplifications, or translocations of large regions of the
genome that is referred to as a “structural” or “segmental” aneuploidy [3]. Whole
chromosomal aneuploidies might arise due to random and sporadic chromosome
missegregation events that occur with low frequency during any cell division. The
missegregation levels range from 1/1000 to 1/10,000 in human cells [4].
Meiosis generates haploid gametes through a specialized cell division process
that consists of one round of DNA replication followed by two cell divisions. The
first division, or meiosis I (MI), involves the segregation of homologous chromo-
somes from each other, whereas meiosis II (MII) involves the segregation of the
sister chromatids. Missegregation can also occur in germline cells, and the errors
that arise in meiosis result in aneuploid embryos [5]. This chapter aims to provide
evidence that supports the use of PGT for embryo evaluation and euploid embryo
selection due to a positive correlation with fertilization rates.
2. Incidence of aneuploidy
Errors in meiotic chromosome segregation frequently occur during oogenesis
(�20%), especially during the first meiotic division; this incidence of meiotic errors
in oocytes is more elevated in women with advanced maternal age and may be due
to the prolonged time that oocytes spend arrested at meiosis I stage, before ovula-
tion [6]. However, some patterns of nondisjunction appear to be chromosome-
specific; almost all cases of trisomy 16 are linked to errors at maternal MI, while MII
errors are surprisingly common in trisomy 18. Oppositely, in sperm the incidence of
aneuploidy is only 2%. Another considerable percentage of errors (�20%) arise
during the first mitosis after fertilization. Among clinically recognized spontaneous
abortions (fetal deaths occurring between 6 and 8 weeks and 20 weeks gestation),
the incidence increases to �50% [7]; the most common specific abnormalities are
sex-chromosome monosomy (45,X), accounting for nearly 10% of all spontaneous
abortions, and trisomies 16, 21, and 22, which together constitute 50% of all triso-
mies identified in spontaneous abortions. The incidence among stillbirths (fetal
Chr Case report References
1 Pure duplication 1q41-qter: further delineation of trisomy 1q syndromes




Partial trisomy 2q: two cases
[12, 13];
[14]
3 Duplication 3p syndrome: reports of three cases and review of the literature [15–17]
4 Patient with trisomy 4p




5 Trisomy 5p: reports of four cases report and review of the literature [21–23]
6 De novo “pure” partial trisomy (6)(p22.3!pter): case report/review
Familial trisomy 6p in mother and daughter
[24]
[25]
7 Interstitial de novo tandem duplication of 7 (q31.1-q35)
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deaths occurring between 20 weeks gestation and term) is 4% with the types of
abnormality being similar to those identified in newborns, and 0.3% of live-born
are aneuploid with the most common abnormalities being trisomies 21, 18, and 13
and sex-chromosome trisomies 47,XXX, 47,XXY, and 47,XYY [5, 8].
2.1 Aneuploidies and live births
Although about 65% of chromosomally abnormal embryos culminate in sponta-
neous miscarriages, there is still evidence of live births harboring crucial aneu-
ploidies. Table 1 describes cases that are well documented.
3. Impact of aneuploidy on the efficiency of ART
Assisted reproduction is a solution in many of the growing cases of infertile
couples worldwide. A high rate of embryos produced in vitro presents chromosomal
aneuploidy (50%), and such aneuploid embryos have reduced the potential for
achieving a viable pregnancy. Such abnormalities are recognized as the leading
cause of implantation failure and spontaneous miscarriage [60]. Among concep-
tions that survive to term, aneuploidy is the leading genetic cause of developmental
Chr Case report References
8 Trisomy 8: report of four cases [28]
9 Pure 9p trisomy derived from a terminal balanced unreciprocal translocation
Trisomy 9: review and report of two new cases
[29]
[30]
10 Distal 10q trisomy with copy number gain in chromosome region 10q23.1–10q25.1
Proximal 10q duplication in a child with severe central hypotonia
[31]
[32]
11 Partial 11q trisomy syndrome: two cases [33, 34]
12 Clinical report of a patient with de novo trisomy 12q23.1q24.33 [35]
13 Trisomy 13, Patau’s syndrome: reports of three cases [36–38]
14 Partial proximal trisomy 14 [39]
15 Duplication of distal 15q: reports of 14 cases [40, 41]
16 Partial trisomy/long arm of chromosome 16: case report/review of literature
Complete trisomy 16: a case report
[42]
[43]
17 A 790 kb chromosome 17p13.3 microduplication: case report/literature review [44, 45]
18 Trisomy 18, Edward’s syndrome: reports of five cases and discussion [46–48]
19 Three cases of trisomy 19 [49, 50]
20 20q11.2 duplication syndrome and pure trisomy 20p [51, 52]
21 Cardiovascular and general health status of adults with trisomy 21 [53]
22 Trisomy 22 syndrome: a report of four cases in newborns and literature review [54–56]
X Fragile X syndrome: a case report/review of clinical and molecular diagnoses [57, 58]
Y Morphology and pathogenesis of 47,XYY/47,XY patients super male syndrome [59]
Chr, chromosome number.
Table 1.
Case reports of live births with complete or partial chromosomal abnormalities (mosaic or multiple aberrations
are not considered).
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of 46 chromosomes. Human gametes (or sex cells), sperm and oocytes, are haploid
and contain only one set of 23 chromosomes.
Aneuploidies can occur either by chromosome gains (trisomies) and losses
(monosomies) due to chromosome segregation errors, the so-called “whole chro-
mosomal” aneuploidy or due to rearrangements of chromosomal parts, often
accompanied by deletions, amplifications, or translocations of large regions of the
genome that is referred to as a “structural” or “segmental” aneuploidy [3]. Whole
chromosomal aneuploidies might arise due to random and sporadic chromosome
missegregation events that occur with low frequency during any cell division. The
missegregation levels range from 1/1000 to 1/10,000 in human cells [4].
Meiosis generates haploid gametes through a specialized cell division process
that consists of one round of DNA replication followed by two cell divisions. The
first division, or meiosis I (MI), involves the segregation of homologous chromo-
somes from each other, whereas meiosis II (MII) involves the segregation of the
sister chromatids. Missegregation can also occur in germline cells, and the errors
that arise in meiosis result in aneuploid embryos [5]. This chapter aims to provide
evidence that supports the use of PGT for embryo evaluation and euploid embryo
selection due to a positive correlation with fertilization rates.
2. Incidence of aneuploidy
Errors in meiotic chromosome segregation frequently occur during oogenesis
(�20%), especially during the first meiotic division; this incidence of meiotic errors
in oocytes is more elevated in women with advanced maternal age and may be due
to the prolonged time that oocytes spend arrested at meiosis I stage, before ovula-
tion [6]. However, some patterns of nondisjunction appear to be chromosome-
specific; almost all cases of trisomy 16 are linked to errors at maternal MI, while MII
errors are surprisingly common in trisomy 18. Oppositely, in sperm the incidence of
aneuploidy is only 2%. Another considerable percentage of errors (�20%) arise
during the first mitosis after fertilization. Among clinically recognized spontaneous
abortions (fetal deaths occurring between 6 and 8 weeks and 20 weeks gestation),
the incidence increases to �50% [7]; the most common specific abnormalities are
sex-chromosome monosomy (45,X), accounting for nearly 10% of all spontaneous
abortions, and trisomies 16, 21, and 22, which together constitute 50% of all triso-
mies identified in spontaneous abortions. The incidence among stillbirths (fetal
Chr Case report References
1 Pure duplication 1q41-qter: further delineation of trisomy 1q syndromes




Partial trisomy 2q: two cases
[12, 13];
[14]
3 Duplication 3p syndrome: reports of three cases and review of the literature [15–17]
4 Patient with trisomy 4p




5 Trisomy 5p: reports of four cases report and review of the literature [21–23]
6 De novo “pure” partial trisomy (6)(p22.3!pter): case report/review
Familial trisomy 6p in mother and daughter
[24]
[25]
7 Interstitial de novo tandem duplication of 7 (q31.1-q35)
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deaths occurring between 20 weeks gestation and term) is 4% with the types of
abnormality being similar to those identified in newborns, and 0.3% of live-born
are aneuploid with the most common abnormalities being trisomies 21, 18, and 13
and sex-chromosome trisomies 47,XXX, 47,XXY, and 47,XYY [5, 8].
2.1 Aneuploidies and live births
Although about 65% of chromosomally abnormal embryos culminate in sponta-
neous miscarriages, there is still evidence of live births harboring crucial aneu-
ploidies. Table 1 describes cases that are well documented.
3. Impact of aneuploidy on the efficiency of ART
Assisted reproduction is a solution in many of the growing cases of infertile
couples worldwide. A high rate of embryos produced in vitro presents chromosomal
aneuploidy (50%), and such aneuploid embryos have reduced the potential for
achieving a viable pregnancy. Such abnormalities are recognized as the leading
cause of implantation failure and spontaneous miscarriage [60]. Among concep-
tions that survive to term, aneuploidy is the leading genetic cause of developmental
Chr Case report References
8 Trisomy 8: report of four cases [28]
9 Pure 9p trisomy derived from a terminal balanced unreciprocal translocation
Trisomy 9: review and report of two new cases
[29]
[30]
10 Distal 10q trisomy with copy number gain in chromosome region 10q23.1–10q25.1
Proximal 10q duplication in a child with severe central hypotonia
[31]
[32]
11 Partial 11q trisomy syndrome: two cases [33, 34]
12 Clinical report of a patient with de novo trisomy 12q23.1q24.33 [35]
13 Trisomy 13, Patau’s syndrome: reports of three cases [36–38]
14 Partial proximal trisomy 14 [39]
15 Duplication of distal 15q: reports of 14 cases [40, 41]
16 Partial trisomy/long arm of chromosome 16: case report/review of literature
Complete trisomy 16: a case report
[42]
[43]
17 A 790 kb chromosome 17p13.3 microduplication: case report/literature review [44, 45]
18 Trisomy 18, Edward’s syndrome: reports of five cases and discussion [46–48]
19 Three cases of trisomy 19 [49, 50]
20 20q11.2 duplication syndrome and pure trisomy 20p [51, 52]
21 Cardiovascular and general health status of adults with trisomy 21 [53]
22 Trisomy 22 syndrome: a report of four cases in newborns and literature review [54–56]
X Fragile X syndrome: a case report/review of clinical and molecular diagnoses [57, 58]
Y Morphology and pathogenesis of 47,XYY/47,XY patients super male syndrome [59]
Chr, chromosome number.
Table 1.
Case reports of live births with complete or partial chromosomal abnormalities (mosaic or multiple aberrations
are not considered).
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disabilities and mental retardation [5]. Table 2 describes data from different infer-
tility centers predominantly showing that aneuploidy rates are similar.
The relatively high aneuploidy rate observed in human embryos after an IVF/
ICSI cycle has been attributed to the technique itself since this prevalence seems to
be lower in natural conceptions [61]. Many hypotheses have been proposed that
may explain these findings: (1) controlled ovarian stimulation treatments, (2) fac-
tors related to the ICSI technique and (3) lab conditions as embryo culture.
3.1 Ovarian stimulation and the incidence of embryo aneuploidy
To increase the number of oocytes that can be retrieved for IVF, gonadotrophins
are commonly used for superovulation in humans. Exogenous administration of
gonadotrophins results in higher concentrations of steroids that may affect oocyte
and embryo quality. Ovarian stimulation effects have been well characterized
mainly in the murine model and have shown that aggressive stimulation leads to a
poorer embryo development potential that could increase the chromosomal abnor-
mality rate [79]. In humans, studies are scarce and less conclusive. A recent study in
a population of young normovulatory women showed that a high ovarian response
after controlled ovarian stimulation with moderate gonadotropin doses did not
increase the embryo aneuploidy rate. Indeed, the higher the ovarian response, the
more the euploid embryos obtained [80]; the remaining question is whether this
can also be extrapolated to infertile patients with good ovarian reserve.
3.2 Intracytoplasmic sperm injection (ICSI) technique and the incidence of
embryo aneuploidy
ICSI has become critical for the treatment of severe male infertility. The princi-
pal feature of ICSI is the direct injection of spermatozoa into an oocyte, which
facilitates the production of fertilized embryos regardless of semen characteristics,
such as sperm concentration and motility. However, the chromosomal integrity of
ICSI zygotes is degraded compared to zygotes obtained from an in vitro fertilization
[81, 82]. During the ICSI procedure, a sperm pretreatment is performed to mimic
the conditions of natural fertilization and support the progression of fertilization
effects. Studies on mouse models revealed that the chromosomal integrity of
zygotes derived from ICSI without any pretreatment of spermatozoa was impaired
in comparison with zygotes derived from conventional IVF [83]; even the culture
sperm conditions may affect the chromosomal stability of the embryo [84]. Chro-
mosomal damage may occur due to the injection of non-capacitated, acrosome-
intact spermatozoa, so to reduce the risk of chromosomal aberrations during the
ICSI procedure, it is crucial that sperm capacitation and the acrosome reaction be
appropriately artificially induced in the proper medium before use [85].
3.3 Embryo culture and the incidence of embryo aneuploidy
Fertilization and embryo development in vitro have the potential to introduce
(often inadvertently) stress which cannot only impair embryo development in the
laboratory but also have downstream effects after transfer.
In vivo, the developing preimplantation embryo is exposed to gradients of
nutrients, hormones, cytokines, and growth factors as it progresses through the
fallopian tube to the uterus. Within the lumen of the female tract, the embryo
resides in a few 100 nanoliters of a complex viscous fluid characterized by high
levels of mucins, albumin, and glycosaminoglycans and by reduced levels of oxygen
40
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274 (US) 3 72.3 39.8* 44.5* 22, 16, 7 6, 9, 19 [68]
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0 74 56# 44# 16, 21, 22, 15, 19 No data [73]
3 83 49# 51# 22, 16, 19, 21, 13
5 58 47# 53# 22, 16, 15, 21, 19
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times more frequent
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3 47.6+
5 or 6 80++
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6, 5, Y, 3 [75]
5/6 45.2 52# 48# 22, X, 16, 18, 21
1025
(Mexico)
3/5 43.9 59.3# 40.7# 16, 21, 22, 19,
15, 20
8, 4, 3, 2, 7, 1 Current
study
*Percentage of the total number of samples.
#Percentage of the total number of aneuploid samples.
+Rate from the previous stage of development, PBs to blastomere.
++Rate from the previous stage of development blastomere to TE, PBs = polar bodies,TE = trophectoderm.
For the current study, infertile patients who underwent ART at the Ingenes Institute were included. The
patients were clinically evaluated according to a standardized protocol that includes family and personal clinical
history. The protocol was approved by the Ethics Committee of the Ingenes Institute, and a signed informed
consent was obtained from all patients. IVF, embryo biopsy, and mCGH were performed according to the
standard protocols of the Institute Ingenes as previously described [76, 77]. Only optimal morphological embryos
were considered for this study. Selection and embryo transfer were done on Day 3 or Day 5 of development
according to the embryo morphological assessment, using the criteria established by the Istanbul consensus
Workshop on Embryo Assessment [78].
Table 2.
Aneuploidy rates of different IVF clinics around the world; when mentioned, the most commonly affected
chromosomes are listed.
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disabilities and mental retardation [5]. Table 2 describes data from different infer-
tility centers predominantly showing that aneuploidy rates are similar.
The relatively high aneuploidy rate observed in human embryos after an IVF/
ICSI cycle has been attributed to the technique itself since this prevalence seems to
be lower in natural conceptions [61]. Many hypotheses have been proposed that
may explain these findings: (1) controlled ovarian stimulation treatments, (2) fac-
tors related to the ICSI technique and (3) lab conditions as embryo culture.
3.1 Ovarian stimulation and the incidence of embryo aneuploidy
To increase the number of oocytes that can be retrieved for IVF, gonadotrophins
are commonly used for superovulation in humans. Exogenous administration of
gonadotrophins results in higher concentrations of steroids that may affect oocyte
and embryo quality. Ovarian stimulation effects have been well characterized
mainly in the murine model and have shown that aggressive stimulation leads to a
poorer embryo development potential that could increase the chromosomal abnor-
mality rate [79]. In humans, studies are scarce and less conclusive. A recent study in
a population of young normovulatory women showed that a high ovarian response
after controlled ovarian stimulation with moderate gonadotropin doses did not
increase the embryo aneuploidy rate. Indeed, the higher the ovarian response, the
more the euploid embryos obtained [80]; the remaining question is whether this
can also be extrapolated to infertile patients with good ovarian reserve.
3.2 Intracytoplasmic sperm injection (ICSI) technique and the incidence of
embryo aneuploidy
ICSI has become critical for the treatment of severe male infertility. The princi-
pal feature of ICSI is the direct injection of spermatozoa into an oocyte, which
facilitates the production of fertilized embryos regardless of semen characteristics,
such as sperm concentration and motility. However, the chromosomal integrity of
ICSI zygotes is degraded compared to zygotes obtained from an in vitro fertilization
[81, 82]. During the ICSI procedure, a sperm pretreatment is performed to mimic
the conditions of natural fertilization and support the progression of fertilization
effects. Studies on mouse models revealed that the chromosomal integrity of
zygotes derived from ICSI without any pretreatment of spermatozoa was impaired
in comparison with zygotes derived from conventional IVF [83]; even the culture
sperm conditions may affect the chromosomal stability of the embryo [84]. Chro-
mosomal damage may occur due to the injection of non-capacitated, acrosome-
intact spermatozoa, so to reduce the risk of chromosomal aberrations during the
ICSI procedure, it is crucial that sperm capacitation and the acrosome reaction be
appropriately artificially induced in the proper medium before use [85].
3.3 Embryo culture and the incidence of embryo aneuploidy
Fertilization and embryo development in vitro have the potential to introduce
(often inadvertently) stress which cannot only impair embryo development in the
laboratory but also have downstream effects after transfer.
In vivo, the developing preimplantation embryo is exposed to gradients of
nutrients, hormones, cytokines, and growth factors as it progresses through the
fallopian tube to the uterus. Within the lumen of the female tract, the embryo
resides in a few 100 nanoliters of a complex viscous fluid characterized by high
levels of mucins, albumin, and glycosaminoglycans and by reduced levels of oxygen
40


















87 (India) 3 54 14.9* 42.5* 22, 18 No data [62]
150
(Japan)
5 40.6 18* 21.3* 15, 22, 21, 16, 18 4, 12 [63]
52 (UK) 5 40.4 51.3# 48.7# 22, 16, 15, 18,
21, X
1, 2, 5, 10, 17,
19
[64]
12 (UK) 3 75 22* 11* 20, 21, 22 6 [65]
5879
(USA)
3 70.6 No data No data No data No data [66]
5 47.8
759 (UK) 3 64.6 40# 60# 16, 22, 21, 4, 5 4, 6 [67]
274 (US) 3 72.3 39.8* 44.5* 22, 16, 7 6, 9, 19 [68]




5 36.3 5.34* 5* 16, 22, XXX, 9 3, 7, 8, 10, 12,
18, 20
[70]




5 48.9 15.96* 4* 15, 16, 21, 4 1, 2, 3, 5, 8, 9,
10, 11, 12, 14,
17, 20, 22, X, Y










No data No data No data 13, 15, 16, 18,
19, 21, 22
1, 12, 3 [72]
2204
(UK)
0 74 56# 44# 16, 21, 22, 15, 19 No data [73]
3 83 49# 51# 22, 16, 19, 21, 13
5 58 47# 53# 22, 16, 15, 21, 19
21 sets
(Italy)
0/1 97.4 Chromosomal loss three
times more frequent
than gain
22, 15, 16, 17 No data [74]
3 47.6+
5 or 6 80++
195 (USA) 0/1 65.5 39.86# 60.14# 22, 13, 15, 16,
19, 21
6, 5, Y, 3 [75]
5/6 45.2 52# 48# 22, X, 16, 18, 21
1025
(Mexico)
3/5 43.9 59.3# 40.7# 16, 21, 22, 19,
15, 20
8, 4, 3, 2, 7, 1 Current
study
*Percentage of the total number of samples.
#Percentage of the total number of aneuploid samples.
+Rate from the previous stage of development, PBs to blastomere.
++Rate from the previous stage of development blastomere to TE, PBs = polar bodies,TE = trophectoderm.
For the current study, infertile patients who underwent ART at the Ingenes Institute were included. The
patients were clinically evaluated according to a standardized protocol that includes family and personal clinical
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consent was obtained from all patients. IVF, embryo biopsy, and mCGH were performed according to the
standard protocols of the Institute Ingenes as previously described [76, 77]. Only optimal morphological embryos
were considered for this study. Selection and embryo transfer were done on Day 3 or Day 5 of development
according to the embryo morphological assessment, using the criteria established by the Istanbul consensus
Workshop on Embryo Assessment [78].
Table 2.
Aneuploidy rates of different IVF clinics around the world; when mentioned, the most commonly affected
chromosomes are listed.
41
Aneuploidy Rates Inversely Correlate with Implantation during In Vitro…
DOI: http://dx.doi.org/10.5772/intechopen.81884
(typically 2–8%). The embryo is in constant motion, moved by gentle ciliated and
muscular action of the female tract [86]. This scenario is in stark contrast to the
laboratory environment, where typical gametes and embryos are exposed to rela-
tively large volumes of culture medium, remain static during culture while resting
on a polystyrene substrate, and create unstirred layers where the end products of
metabolism concentrate and nutrients become limited [87].
Embryos are sensitive to both chemical and physical signals within their microen-
vironment. Factors within the laboratory as oxygen level, ammonium released from
amino acids into the culture, poor laboratory air quality, temperature and pH, oil
overlay, embryo culture volume/density, the static nature of culture, light, or even
mechanical factors as pipetting, can negatively impact gametes and embryos and
generate stress. When more than one stress factor is present in the laboratory, more
negative synergies can result, and these factors play a significant role in influencing
the development and events post transfer [88]. For example, recent studies have
reported that a decrease in temperature has the potential to affect the stability of the
oocyte’s meiotic spindle, reducing fertilization rates, delaying embryo development,
and decreasing clinical pregnancy rates [89]. However, more studies are needed to
demonstrate the impact of embryo culture on aneuploidy rates.
4. Aneuploidy detection: techniques for PGT
PGT is the genetic diagnosis analysis performed to identify euploid embryos
before uterine transfer [90]. PGT determines the numeric chromosomal constitu-
tion of a cellular biopsy sample obtained from a cultured embryo to determine its
competence [91, 92].
PGT was first described in 1990 by Handyside et al. [93] when the sex of the six-
to eight-cell stage embryos from two couples with a known risk of transmitting X-
linked diseases was assessed by DNA amplification of a Y chromosome-specific
repeat sequence. The earliest PGT studies in the 2000s were based on the fluores-
cence in situ hybridization (FISH) technique where 3–12 chromosomes can be
analyzed on the cleavage stage or polar body biopsies [90]. Those studies had
disappointing results in clinical practice since it had no beneficial effect on live birth
rate after IVF [94]. The major drawback of FISH-based PGT is the limited number
of chromosomes that can be analyzed considering that aneuploidy can affect any of
the 22 autosomes and both sex chromosomes [95]; consequently, there have been
dramatic improvements in PGT technology to make it valuable for clinical practice.
Nowadays, several methodologies for 24-chromosome analysis are available for
clinical use that aim to increase implantation rates and decrease miscarriage rates
associated with IVF [90]: microarray comparative genomic hybridization (mCGH),
single-nucleotide polymorphism (SNP) microarray, real-time polymerase chain
reaction (qPCR), and next-generation sequencing (NGS) [96, 97]. This review will
focus on the relevant aspects of the PGT techniques used in our laboratory.
4.1 Microarray comparative genomic hybridization (mCGH)
mCGH is a ratio labeling protocol to compare the DNA product of a clinical
sample to a healthy control. For PGT, biopsied embryonic cells must be lysed to
extract the sample’s DNA, which will be further amplified by a protocol that
provides whole genome coverage [90, 95, 98]. The resulting DNA products are
co-hybridized with a standard DNA control sample (46,XY and 46,XX) with a
series of site-specific fluorophores on a microarray chip with approximately 4000
markers spaced throughout the genome [90]. Then, a confocal laser platform
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detects the relative color intensity, and a bioinformatics compares the intensity of
each fluorophore in the sample versus the control to identify any bias and deter-
mine the ploidy status of the sample [90, 95, 98].
The mCGH analysis reports the ratio of sample DNA to a reference DNA, as a
chromosomic profile where the molecular karyotype is represented. Usually, the
sample DNA is labeled with a green fluorescent dye, while the reference DNA
sample is tagged red [99]. Thus, diploid embryos will have a relatively equal ratio of
green-to-red fluorescence in every pair of chromosomes, represented as a continu-
ous horizontal plot line. Monosomy will be represented as a clear downward devia-
tion in the plotted line, indicating a relative lack of green-to-red signal intensity; in
contrary, a trisomy will be displayed as an upward deviation in the plotted line due
to a relative increase in the green-to-red signal intensity.
The specificity rate of mCGH-based PGT is about 99% [90]. The test results can
be available within 12–15 h, considering that the entire analysis can be performed
during this short time frame [90, 91]. Additionally, brand-specific features are
offered by each manufacturer: Agilent’s GenetiSure Pre-Screen Microarray offers a
detection rate of 100% for aberrations >10 Mb and 89% for >5.3 Mb [100];
KaryoLite BoBs Kit from Perkin Elmer uses an alternative BACs-on-Beads technol-
ogy and results are interpreted by the BoBsoft™ analysis software [99]; and RHS’s
EmbryoCellect Kit is the only mCGH-based PGT validated for mosaicism detection
[101]. Recently, Illumina’s 24sure PGS Microarray had been discontinued, and the
NGS-based VeriSeq PGS is now offered as an alternative solution [102].
mCGH entails some disadvantages: first, the embryo sample requires a previous
whole genome amplification (WGA) process to support single-cell diagnostics by
mCGH [95], raising the possibility of introducing errors during the amplification
[91]; second, mCGH is a semiquantitative technique that only reports the ratio of
sample DNA to a reference DNA; it is to say that only imbalances in DNA content
can be identified. Therefore, mCGH is unable to detect uniparental disomic or
triploid embryos as it cannot discriminate between 46,XX from 69,XXX, and 46,
XY from 69,XXY [90, 91, 95]. Last, the mCGH used for PGS cannot identify
structural chromosome aberrations or diagnose mosaicism in a trophectoderm
sample [90].
4.2 Next-generation sequencing (NGS)
NGS refers to the emerging technology of non-Sanger-based DNA sequencing
that allows the sequence in parallel millions of DNA strands with high-throughput
yield. In the field of ART, this powerful tool is being applied for PGT to replace
cytogenetic microarrays [98, 102].
Different platforms are commercially available for NGS with different techno-
logical approaches. Illumina’s MiSeq NGS platform applies a sequencing-by-
synthesis method, where DNA is attached and amplified in situ to be subsequently
used as a template for synthetic sequencing with fluorescent-labeled reversible-
terminator nucleotides [103]. Ion Torrent NGS technology, commercialized by
ThermoFisher Scientific, is based on collecting data by sensing the hydrogen ions
that are released as by-products when nucleotides are incorporated by a template-
directed DNA polymerase synthesis on an ion chip [104].
Despite the dissimilarities between platforms, the common basis of chromosome
copy number analysis by NGS is the fragmentation of the amplified DNA sample
into small segments of 100–200 base pairs that are further sequenced in parallel
until the number of reads covering a determined position in the genome is attained,
in general, a 30 coverage (sequencing each base pair 30 times) ensures sufficient
accuracy. The sequence data obtained are then compared with a reference genome
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(typically 2–8%). The embryo is in constant motion, moved by gentle ciliated and
muscular action of the female tract [86]. This scenario is in stark contrast to the
laboratory environment, where typical gametes and embryos are exposed to rela-
tively large volumes of culture medium, remain static during culture while resting
on a polystyrene substrate, and create unstirred layers where the end products of
metabolism concentrate and nutrients become limited [87].
Embryos are sensitive to both chemical and physical signals within their microen-
vironment. Factors within the laboratory as oxygen level, ammonium released from
amino acids into the culture, poor laboratory air quality, temperature and pH, oil
overlay, embryo culture volume/density, the static nature of culture, light, or even
mechanical factors as pipetting, can negatively impact gametes and embryos and
generate stress. When more than one stress factor is present in the laboratory, more
negative synergies can result, and these factors play a significant role in influencing
the development and events post transfer [88]. For example, recent studies have
reported that a decrease in temperature has the potential to affect the stability of the
oocyte’s meiotic spindle, reducing fertilization rates, delaying embryo development,
and decreasing clinical pregnancy rates [89]. However, more studies are needed to
demonstrate the impact of embryo culture on aneuploidy rates.
4. Aneuploidy detection: techniques for PGT
PGT is the genetic diagnosis analysis performed to identify euploid embryos
before uterine transfer [90]. PGT determines the numeric chromosomal constitu-
tion of a cellular biopsy sample obtained from a cultured embryo to determine its
competence [91, 92].
PGT was first described in 1990 by Handyside et al. [93] when the sex of the six-
to eight-cell stage embryos from two couples with a known risk of transmitting X-
linked diseases was assessed by DNA amplification of a Y chromosome-specific
repeat sequence. The earliest PGT studies in the 2000s were based on the fluores-
cence in situ hybridization (FISH) technique where 3–12 chromosomes can be
analyzed on the cleavage stage or polar body biopsies [90]. Those studies had
disappointing results in clinical practice since it had no beneficial effect on live birth
rate after IVF [94]. The major drawback of FISH-based PGT is the limited number
of chromosomes that can be analyzed considering that aneuploidy can affect any of
the 22 autosomes and both sex chromosomes [95]; consequently, there have been
dramatic improvements in PGT technology to make it valuable for clinical practice.
Nowadays, several methodologies for 24-chromosome analysis are available for
clinical use that aim to increase implantation rates and decrease miscarriage rates
associated with IVF [90]: microarray comparative genomic hybridization (mCGH),
single-nucleotide polymorphism (SNP) microarray, real-time polymerase chain
reaction (qPCR), and next-generation sequencing (NGS) [96, 97]. This review will
focus on the relevant aspects of the PGT techniques used in our laboratory.
4.1 Microarray comparative genomic hybridization (mCGH)
mCGH is a ratio labeling protocol to compare the DNA product of a clinical
sample to a healthy control. For PGT, biopsied embryonic cells must be lysed to
extract the sample’s DNA, which will be further amplified by a protocol that
provides whole genome coverage [90, 95, 98]. The resulting DNA products are
co-hybridized with a standard DNA control sample (46,XY and 46,XX) with a
series of site-specific fluorophores on a microarray chip with approximately 4000
markers spaced throughout the genome [90]. Then, a confocal laser platform
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detects the relative color intensity, and a bioinformatics compares the intensity of
each fluorophore in the sample versus the control to identify any bias and deter-
mine the ploidy status of the sample [90, 95, 98].
The mCGH analysis reports the ratio of sample DNA to a reference DNA, as a
chromosomic profile where the molecular karyotype is represented. Usually, the
sample DNA is labeled with a green fluorescent dye, while the reference DNA
sample is tagged red [99]. Thus, diploid embryos will have a relatively equal ratio of
green-to-red fluorescence in every pair of chromosomes, represented as a continu-
ous horizontal plot line. Monosomy will be represented as a clear downward devia-
tion in the plotted line, indicating a relative lack of green-to-red signal intensity; in
contrary, a trisomy will be displayed as an upward deviation in the plotted line due
to a relative increase in the green-to-red signal intensity.
The specificity rate of mCGH-based PGT is about 99% [90]. The test results can
be available within 12–15 h, considering that the entire analysis can be performed
during this short time frame [90, 91]. Additionally, brand-specific features are
offered by each manufacturer: Agilent’s GenetiSure Pre-Screen Microarray offers a
detection rate of 100% for aberrations >10 Mb and 89% for >5.3 Mb [100];
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ogy and results are interpreted by the BoBsoft™ analysis software [99]; and RHS’s
EmbryoCellect Kit is the only mCGH-based PGT validated for mosaicism detection
[101]. Recently, Illumina’s 24sure PGS Microarray had been discontinued, and the
NGS-based VeriSeq PGS is now offered as an alternative solution [102].
mCGH entails some disadvantages: first, the embryo sample requires a previous
whole genome amplification (WGA) process to support single-cell diagnostics by
mCGH [95], raising the possibility of introducing errors during the amplification
[91]; second, mCGH is a semiquantitative technique that only reports the ratio of
sample DNA to a reference DNA; it is to say that only imbalances in DNA content
can be identified. Therefore, mCGH is unable to detect uniparental disomic or
triploid embryos as it cannot discriminate between 46,XX from 69,XXX, and 46,
XY from 69,XXY [90, 91, 95]. Last, the mCGH used for PGS cannot identify
structural chromosome aberrations or diagnose mosaicism in a trophectoderm
sample [90].
4.2 Next-generation sequencing (NGS)
NGS refers to the emerging technology of non-Sanger-based DNA sequencing
that allows the sequence in parallel millions of DNA strands with high-throughput
yield. In the field of ART, this powerful tool is being applied for PGT to replace
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Different platforms are commercially available for NGS with different techno-
logical approaches. Illumina’s MiSeq NGS platform applies a sequencing-by-
synthesis method, where DNA is attached and amplified in situ to be subsequently
used as a template for synthetic sequencing with fluorescent-labeled reversible-
terminator nucleotides [103]. Ion Torrent NGS technology, commercialized by
ThermoFisher Scientific, is based on collecting data by sensing the hydrogen ions
that are released as by-products when nucleotides are incorporated by a template-
directed DNA polymerase synthesis on an ion chip [104].
Despite the dissimilarities between platforms, the common basis of chromosome
copy number analysis by NGS is the fragmentation of the amplified DNA sample
into small segments of 100–200 base pairs that are further sequenced in parallel
until the number of reads covering a determined position in the genome is attained,
in general, a 30 coverage (sequencing each base pair 30 times) ensures sufficient
accuracy. The sequence data obtained are then compared with a reference genome
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and counted by bioinformatics software. The copy number of a specific chromo-
some should be proportional to the number of counted sequences; therefore, an
increase or reduction in the number of reads will, respectively, represent a trisomy
or monosomy [97, 99].
NGS allows to simultaneously perform both qualitative and quantitative ana-
lyses of multiple embryos with high-resolution data for chromosomal analysis
[96, 97]. The higher sensitivity and precision offered by NGS [96, 105, 106] makes
possible to exclude embryos with mosaicism [105, 106] and partial aneuploidies or
triploidies [106], improving pregnancy outcomes due to its enhanced capability for
detecting those challenging abnormalities.
PGT by NGS can predict not only chromosome copy number for the diagnosis of
whole chromosome aneuploidy with 99.98% assignment consistency [97] but also
single-gene disorders [107], abnormalities of the mitochondrial genome [108], and
segmental chromosome imbalances [97, 99]. Balanced chromosomal
rearrangements cannot be detected by NGS [97].
The increasing demand and accelerated development are continuously reducing
the cost of NGS technology [109]. Also, potential cost-benefit ratios can be achieved
when the full sequencing capacity of the apparatus is exploited [96, 97, 99].
Furthermore, molecular tools, like barcoding, are being implemented to allow
multiplex high-throughput sequencing [110]; this promising strategy will reduce
the diagnosis’ cost per patient by performing simultaneous analysis of multiple
embryos from different patients [97].
5. Aneuploidy and women age
In our study, by analyzing the mCGH data, the total number of aneuploidies
was found to be 734, and from these, 641 (87.3%) were derived from patients
and 93 (12.7%) from donors. Overall, this study displayed similar rates of
monosomies, trisomies, double aneuploidies, and multiple aneuploidies. The
total number of monosomies (191) was similar to the number of trisomies (194),
accounting for 26 and 26.4% of the total aneuploidies, correspondingly.
Furthermore, the total number of double (165) and multiple (184) aneuploidies
was also very similar, accounting for 22.5 and 25.1% of the total aneuploidies,
correspondingly. Nevertheless, it is worth noticing that when considering only the
donor group, monosomies seem to be more prevalent: 38.7% of the total donors’
aneuploidies were monosomies vs. 24.7% of trisomies, 16.1% of double aneu-
ploidies, and 20.4% of multiple aneuploidies; what is more, the percentage of
monosomies in the donor group is higher than that of the monosomies of the patient
group (38.7 vs. 24.3%). The most common monosomies affected chromosomes 15,
16, and 22, whereas the most common trisomy affected chromosomes 16, 19, and 21
(Table 3).
It has been shown that the lowest risk for embryonic aneuploidy is between ages
26 and 30, with aneuploidy rates steadily increasing with maternal age after
26 years of age [111] and leaping significantly from the age of 39 [112]. For this
reason, women of advanced maternal age are encouraged to favor oocyte donation
to yield high-quality viable embryos.
Interestingly, some studies have identified that women of younger ages possess
an increased prevalence of aneuploidy, with >40% of aneuploidy in women of
23 years and under [111] and 58% of aneuploidy in women of <31 years of age. In
the current study, both the donor (≤29 years) and the patient group of ≤29 years
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displayed high aneuploid rates, 28.5 and 27.4%, respectively (Table 4). Given the
high rates of aneuploidy in younger women, attention should be paid in detecting
aneuploidy in embryos from women of young maternal age, especially since this
group of patients is not routinely encouraged to perform a PGT. Still, whether there
is a difference between the distribution of aneuploidies between donors and
patients remains uncertain.
When stratifying our analysis in age groups (a, ≤29; b, 30–34; c, 35–37; d, 38–40;
e, 41–43; and f, ≥44 years of age), a visible continuous increase in aneuploidy rate
can be observed as maternal age increases (Table 4); furthermore, this increase in
aneuploidy goes hand in hand with a continuous decrease in implantation, as it
can be observed in the decrease of positive beta-human chorionic gonadotropin
(β-hCG) values as age increases (β-hCG values ≥10 mUI/ml from Day 14 after
transference were considered positive).
All Patients Donors
Total 734 641 93
Monosomy 191 (26.0%) 155 (24.3%) 36 (38.7%)
Chr 15 13 13 0
Chr 16 21 18 3
Chr 22 22 22 0
Chr X 10 8 2
Chr Y 40 26 14
Trisomy 194 (26.4%) 171 (26.7%) 23 (24.7%)
+Chr 16 26 24 2
+Chr 18 9 7 2
+Chr 19 23 21 2
+Chr 20 17 13 4
+Chr 21 20 20 0
+Chr 22 19 19 0
+Chr X 10 8 2
+Chr Y 1 1 0
Dual 165 (22.5%) 150 (23.4%) 15 (16.1%)
Multiple 184 (25.1%)a 165 (25.7%)b 19 (20.4%)c
The current study included 441 patients, resulting in 474 cycles. A total of 1629 embryos were analyzed; from those, 54
were excluded due to failed WGA, leaving 1575 embryos for analysis, 1258 from patients, and 317 from donors.
Biopsies were performed at the blastomere (Day 3, patients = 238 and donors = 50) and blastocyst stages (Day 5,
patients = 1020 and donors = 267). Finally, 734 embryos (46.6%) were found to be aneuploid (patients = 641 and
donors = 93). The total number of monosomies and trisomies is provided along with their respective percentages;
furthermore, the number of the most common aneuploidies of the mCGH data is listed.
aNine embryos had completely abnormal mCGH profiles.
bEven embryos had completely abnormal mCGH profiles.
cTwo embryos had completely abnormal mCGH profiles.
Table 3.
Most frequent types of aneuploidies in the mCGH data of the current study.
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and counted by bioinformatics software. The copy number of a specific chromo-
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increase or reduction in the number of reads will, respectively, represent a trisomy
or monosomy [97, 99].
NGS allows to simultaneously perform both qualitative and quantitative ana-
lyses of multiple embryos with high-resolution data for chromosomal analysis
[96, 97]. The higher sensitivity and precision offered by NGS [96, 105, 106] makes
possible to exclude embryos with mosaicism [105, 106] and partial aneuploidies or
triploidies [106], improving pregnancy outcomes due to its enhanced capability for
detecting those challenging abnormalities.
PGT by NGS can predict not only chromosome copy number for the diagnosis of
whole chromosome aneuploidy with 99.98% assignment consistency [97] but also
single-gene disorders [107], abnormalities of the mitochondrial genome [108], and
segmental chromosome imbalances [97, 99]. Balanced chromosomal
rearrangements cannot be detected by NGS [97].
The increasing demand and accelerated development are continuously reducing
the cost of NGS technology [109]. Also, potential cost-benefit ratios can be achieved
when the full sequencing capacity of the apparatus is exploited [96, 97, 99].
Furthermore, molecular tools, like barcoding, are being implemented to allow
multiplex high-throughput sequencing [110]; this promising strategy will reduce
the diagnosis’ cost per patient by performing simultaneous analysis of multiple
embryos from different patients [97].
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In our study, by analyzing the mCGH data, the total number of aneuploidies
was found to be 734, and from these, 641 (87.3%) were derived from patients
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accounting for 26 and 26.4% of the total aneuploidies, correspondingly.
Furthermore, the total number of double (165) and multiple (184) aneuploidies
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ploidies, and 20.4% of multiple aneuploidies; what is more, the percentage of
monosomies in the donor group is higher than that of the monosomies of the patient
group (38.7 vs. 24.3%). The most common monosomies affected chromosomes 15,
16, and 22, whereas the most common trisomy affected chromosomes 16, 19, and 21
(Table 3).
It has been shown that the lowest risk for embryonic aneuploidy is between ages
26 and 30, with aneuploidy rates steadily increasing with maternal age after
26 years of age [111] and leaping significantly from the age of 39 [112]. For this
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23 years and under [111] and 58% of aneuploidy in women of <31 years of age. In
the current study, both the donor (≤29 years) and the patient group of ≤29 years
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displayed high aneuploid rates, 28.5 and 27.4%, respectively (Table 4). Given the
high rates of aneuploidy in younger women, attention should be paid in detecting
aneuploidy in embryos from women of young maternal age, especially since this
group of patients is not routinely encouraged to perform a PGT. Still, whether there
is a difference between the distribution of aneuploidies between donors and
patients remains uncertain.
When stratifying our analysis in age groups (a, ≤29; b, 30–34; c, 35–37; d, 38–40;
e, 41–43; and f, ≥44 years of age), a visible continuous increase in aneuploidy rate
can be observed as maternal age increases (Table 4); furthermore, this increase in
aneuploidy goes hand in hand with a continuous decrease in implantation, as it
can be observed in the decrease of positive beta-human chorionic gonadotropin
(β-hCG) values as age increases (β-hCG values ≥10 mUI/ml from Day 14 after
transference were considered positive).
All Patients Donors
Total 734 641 93
Monosomy 191 (26.0%) 155 (24.3%) 36 (38.7%)
Chr 15 13 13 0
Chr 16 21 18 3
Chr 22 22 22 0
Chr X 10 8 2
Chr Y 40 26 14
Trisomy 194 (26.4%) 171 (26.7%) 23 (24.7%)
+Chr 16 26 24 2
+Chr 18 9 7 2
+Chr 19 23 21 2
+Chr 20 17 13 4
+Chr 21 20 20 0
+Chr 22 19 19 0
+Chr X 10 8 2
+Chr Y 1 1 0
Dual 165 (22.5%) 150 (23.4%) 15 (16.1%)
Multiple 184 (25.1%)a 165 (25.7%)b 19 (20.4%)c
The current study included 441 patients, resulting in 474 cycles. A total of 1629 embryos were analyzed; from those, 54
were excluded due to failed WGA, leaving 1575 embryos for analysis, 1258 from patients, and 317 from donors.
Biopsies were performed at the blastomere (Day 3, patients = 238 and donors = 50) and blastocyst stages (Day 5,
patients = 1020 and donors = 267). Finally, 734 embryos (46.6%) were found to be aneuploid (patients = 641 and
donors = 93). The total number of monosomies and trisomies is provided along with their respective percentages;
furthermore, the number of the most common aneuploidies of the mCGH data is listed.
aNine embryos had completely abnormal mCGH profiles.
bEven embryos had completely abnormal mCGH profiles.
cTwo embryos had completely abnormal mCGH profiles.
Table 3.
Most frequent types of aneuploidies in the mCGH data of the current study.
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6. Remarks
One of the most critical reasons for unsuccessful IVF procedures is implantation
failure due to aneuploid embryos. Aneuploidies are the primary cause of perinatal
death and genetic abnormalities; consequently, the detection of chromosomal dis-
orders constitutes the most frequent indication for PGT. Here, we report on the
aneuploidy rates found in IVF procedures in Mexico. Even though there are studies
that assert that PGT does not improve pregnancy rates, we show that aneuploidy
rates inversely correlate with implantation and that levels of aneuploidy among
high morphological quality embryos are still an important issue to be faced in
everyday ART practice, and this evidence works in favor of continuing to use PGT
analysis.
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Chapter 4
Screening (Bi Test, Triple Test,
Panorama Test) and Amniocentesis
for Early Diagnosis of Congenital
Malformations
Gladys Cristina Al Jashi and Isam Al Jashi
Abstract
The genetic consult is very important in the diagnosis of early fetal
malformations and its complications at birth and after it. Our research is based on a
3-year research on 6097 pregnant women who underwent screening Bi-Test or
Triple Test. We discovered 408 pregnant women who were found positive and
needed amniocentesis for a diagnostic of certitude. Out of them, 14 had a positive
result from which 10 were found with Down syndrome and 4 with Edwards syn-
drome. In Romania, amniocentesis has become the most used method of prenatal
diagnosis for pregnant women at 35 or above with a family history of hereditary
congenital anomalies. However, the latest screening test from maternal blood, the
Panorama test, can discover many malformations (for chromosomes 21, 18, and 13
and the abnormality of the sex chromosome). The accuracy for false positive is 2%
and false negative 98%. In that light, the purpose of our study is to decrease the use
of amniocentesis and to introduce the latest tests (Panoramic) for the early diagno-
sis of fetal malformation, the use of maternal blood, and the avoidance of using
invasive medical procedures.
Keywords: screening Bi-Test,Triple Test, Panorama Test, amniocentesis for early
detection of fetal malformations
1. Introduction
Talking with the patient about his or her family medical history, such as if the
couple had a person with Down syndrome in their family or any other malforma-
tion, is important. That can be considered as a ‘genetic consultation’ in order to find
out about any possible genetic problems before screening or any other tests. The
specialist tries, in the first place, to make the patient understand the nature of his
disease he is confronting, what’s the most possible evolution of it, and last but not
least what are the possibilities of treating it. A major objective of the genetic consult
is to make the patient understand what are the factors that lead to the development
of the disease, what are the mechanisms that transmit the disease, and how high is
the risk of appearance to other family members. The doctor establishes, after run-
ning different tests, the correct diagnosis of the disease, its evolution, its prognosis,
as well as the possibilities of treatment for a higher quality of life.
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The genetic consult is very important in the diagnosis of early fetal
malformations and their complications at birth and after it. The consult is necessary
for pregnant women with high risk in developing a malformation (e.g., if the
woman has in the family history a newborn with malformations, if she gave birth
before to a baby with malformations, if she lives in a toxic environment).
In Romania, it is mandatory that every pregnant woman should do the BI-TEST
or TRIPLE TEST, depending on the pregnancy weeks.
The cytogenetic prenatal diagnosis refers to early detection of intrauterine fetal
abnormalities and genetic malformations, very often determined by genetics, which
complicate and threaten the life of 3–5% of newborn. These abnormalities explain
the 20% deaths in the newborn period and the much higher percentage of deaths in
childhood and puberty [1]. From the fetal abnormalities, 95% are unexpected and
appear at pregnancies that are not considered at risk for these situations. They can
be light or severe.
The severe abnormalities are not compatible with life or can cause a long-term
handicap [2].
There are multiple purposes for the detection of intrauterine prenatal illness
such as:
• Establishing the high-risk diagnosis and possibly the termination of the
pregnancy (abortion), the pregnancy representing a high risk of death both for
the mother and fetus
• Identifying a situation that can influence the date, the place, or the childbirth
method
• Identifying fetuses that will benefit of early pediatric intervention
• Identifying situations that can affect future pregnancies
Opinions are different when it comes to knowing the diagnosis; many families
decide to keep the pregnancy even if there are severe malformations, thinking that
they can fight this problem by taking care of the baby and not terminating the
pregnancy. But most of the families decide to terminate the pregnancies and seek
treatments for future pregnancies.
In conclusion, the most important thing in the prenatal diagnosis is obtaining
very early in the pregnancy of correct informations about the fetus and making a
correct and easy decision in conformity with family principles [3].
The indications for prenatal diagnosis are:
• Pregnancy—women at age of 35 or above
• Husband aged 45 or above
• Past pregnancy with a fetus with chromosomal abnormality
• One of the parents has a chromosomal abnormality including being a carrier of
a balanced translocation or other structural rearrangements
• Down syndrome
• Pregnancies with risk of Mendelian or polygenic diseases (e.g., Tay-Sachs
disease)
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• Abnormal fetus diagnosed by the ultrasound procedure within the first weeks
of pregnancy
• Maternal anxiety
• Determination of fetal risk in pregnancies with high risk for hereditary x-linked
diseases, for that there is not yet a specific prenatal diagnosis (it is obtained
better by determining the Y-chromosomal material with the new ADN
techniques)
• History of two or more abortions without the possibility of effectuation of the
cytogenic analysis to both parents or a noninvasive prenatal diagnosis [4]
The screening programs focus on the most common chromosomal abnormality—
the Down syndrome (trisomy 21)—and they not only detect very often other fetal
abnormalities.
2. The BI-TEST
The screening of the first trimester is a prenatal text that offers informations
about early pregnancy and the risk of the baby to develop some specific chromo-
somal abnormalities—the Down syndrome (trisomy 21) and the Edwards syndrome
(trisomy 18).
The Down syndrome determines a lifetime affectation of the mental and social
development and also some physical modifications. As for Edwards syndrome, it is
a much more severe condition, and often it is fatal until the early age of 1 year [5].
The screening tests from the first trimester of pregnancy do not evaluate the risk
of defects of the neural tube, such as spina bifida.
We do the BI-TEST (the screening of the first trimester in pregnancy) because it
can be done much earlier than other tests of screening; the results can be available
in the first weeks of pregnancy, which offers the parents much more time in taking
the best decision regarding additional tests, medical treatment, and the course of
pregnancy [6].
Normally, the screening of the first trimester (the BI-TEST) is made between
weeks 11 and 14 of pregnancy. The results of the test are formulated as positive or
negative and also like a probability, e.g., 1:5000 risk to have a baby with Down
syndrome. In general, the test is considered positive if the risk is 1:300 or above. The
BI-TEST implies two steps: a blood test that measures the level of two hormones
that are specific in pregnancy (pregnancy-associated plasma protein A (PAPP-A)
and human chorionic gonadotropin (hCG)) and an ultrasound examination which
measures the size of the transparent space behind the neck of the fetus (the nuchal
translucency) [7]. Correlating the values obtained from the blood tests with the
ultrasound examination and some specific parameters of the mother (age, height,
weight, blood pressure, smoking, diabetes, assisted reproductive techniques), the
specialist can calculate the risk of the mother of having a baby with chromosomal
abnormalities [6].
Frequently, a positive result will enforce the performance of secondary
diagnosis tests:
• The chorial biopsy—it is done normally in the first trimester of pregnancy, and
it is an invasive test which implies cropping a piece of the placenta, with a low
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risk of abortion. It is used to detect chromosomal abnormalities, like the Down
syndrome.
• Amniocentesis—it can be used to identify chromosomal abnormalities but also
defects of the neural tube, like spina bifida. During the amniocentesis, which
frequently is done in the second trimester of pregnancy, a small amount of
amniotic liquid is estranged. It also had a low risk of abortion [6].
3. The TRIPLE TEST
A continuance of the BI-TEST from the first trimester and the screening TRIPLE
TEST (made in the second trimester of pregnancy) is more and more often
requested by us. With the help of it, we can evaluate the risks of the baby develop-
ing a neural tube disorder (spina bifida) or chromosomal abnormalities such as the
Down syndrome (trisomy 21) or the Edwards syndrome (trisomy 18) [6].
Between the 15 and 20 weeks of pregnancy (with optimal results in the weeks
16–18), pregnant women can be tested with a simple blood test known as the
TRIPLE TEST (or triple marker test or second trimester screening). It is made in
combination with an ultrasound examination [3].
For the triple marker testing, a blood test is required that will measure the
levels of:
• hCG (human chorionic gonadotropin) secreted by the placenta.
• Unconjugated estriol, a product of the placenta and the fetus.
• Alpha-fetoprotein (AFP gene) produced by the fetus’s liver.
• Sometimes it also tested the inhibin A (produced by the placenta), because it
considerably grows the chances of detection of the Down syndrome, which is
also known as the quadruple test.
The level of each substance present in the blood helps the doctor identify if
the fetus is exposed to the risk of developing congenital disorders and chromosomal
abnormalities. Exactly as in the case of the BI-TEST, multiples of the median (MoM)
is measured depending on the clinical data of the mother (age, height, weight, race,
smoker, age of the fetus) [4]. The results of the tests are available in 2 weeks from the
blood tests. Usually, if the results of the TRIPLE TEST show a high level of alpha-
fetoprotein, it indicates a neural tube defect. The doctor will recommend an ultra-
sound examination of the fetal cranium and spinal cord. The mother is also purposed
to do an amniocentesis, which involves extracting a small amount of amniotic liquid
from the uterus for further investigation.
On the other hand, low levels of alpha-fetoprotein (AFP) and unconjugated
estriol indicate a high risk of Down syndrome. In this situation, it is recommended
that an amniocentesis should be done.
4. Amniocentesis
Amniocentesis is a medical procedure used in prenatal diagnosis of chromosomal
abnormalities, in which a small amount of amniotic fluid which contains fetal
tissues is sampled from the amniotic sac and which is afterward tested.
It is a two-person procedure which requires a lot of experience and care from the
side of the doctor. One of the doctors assures the ultrasound examination, and the
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other doctor places the puncture needle. This way, he can manipulate the needle
with all the attention and care to attain the desired target. There has to be an
incredible collaboration between both doctors, because they have to anticipate each
other’s moves.
Before the procedure, it is mandatory that the sanguine groups ABO and RH be
determined and also to perform an ultrasound examination, which will determine
the number of fetuses, the position and viability, the localization of the placenta, the
amount of amniotic fluid, and the largest amniotic sac that will be punctured and
will assure that the fetus is anatomically normal. Also the gestational age of the fetus
by the fetal biparietal diameter, the length of the thigh bone, and the abdominal
circumference is determined.
Choosing the place of puncture is made after the initial evaluation. When
doing the amniocentesis, it is important to choose the place of the puncture needle
in the amniotic cavity wisely, namely by carefully avoiding the placenta, the
umbilical cord insertion place and the fetus. Colored Doppler ultrasound can
facilitate the choosing of the place for the transplacental puncture, to avoid fetal
hemorrhage.
Diagnosis of chromosomal abnormalities and diagnosis of the neural tube defects
are the most common indications for amniocentesis in the beginning of the second
trimester of pregnancy. As for the evaluation of the fetal pulmonary maturation, it
is the most common indication for amniocentesis in the third trimester [8].
At the end of the first trimester and the beginning of the second trimester, the
indications for amniocentesis are:
• Cytogenetic diagnosis
• Diagnosis of neural tube defects
• Diagnosis of metabolic disorders
At the end of the second trimester and the beginning of the third trimester, the
indications for amniocentesis are:
• Evaluation of the severity of Rh immunization
• Evaluation of fetal pulmonary maturation
• Diagnosis of intra-amniotic infections
• Confirmation of the ruptured membranes
Last, but not the least, the therapeutic purpose of the amniocentesis has indica-
tions in the polyhydramnios drainage and the medical treatment of fetal diseases.
Ultrasound examination (localization of the placenta, fetus, and amniotic liquid
bag) and the insertion of the needle can take up to 20 min. Extraction of the
amniotic liquid can take up to 5 min.
Some women don’t feel pain (painless procedure), while other pregnant women
feel cramps as the needle punctures the uterus or a pressure sensation during the
procedure of extracting amniotic liquid.
Local anesthetic is not normally used. Associated factors to the high level of pain
during the amniocentesis are considered to be maternal anxiety, presence of men-
strual cramps in the past, an anterior amniocentesis, and the insertion of the needle
in the inferior part of the uterus, where the pain is less felt by the patient [9],
although there aren’t any data to support this practice [10].
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5. Panoramic Test
The Panorama Test is a prenatal noninvasive test, which analyzes the fetal DNA
from the maternal blood and establishes the risk of common fetal aneuploidies in
pregnant women, most interestingly the 21, 18, and 13 chromosomes but also the
analyzes the sexual chromosomes X and Y.
Aneuploidies are chromosomal abnormalities characterized by the alteration of
the number of chromosomes, for example, more or less chromosomes instead of the
exact number of chromosomes; the trisomy, when there is an extra chromosome; or
monosomy, when there is missing a chromosome.
Trisomy 21 is caused by the presence of an extra chromosome to the 21st pair,
and it’s known as the Down syndrome. It is the most frequent cause of mental
retardation. The patients with Down syndrome present cardiac disease or other
diseases which require surgical interventions or specific medical treatment. Other
symptoms are, for example, ophthalmological problems [11].
Trisomy 18 is caused by the presence of an extra chromosome to the 18th pair,
and it’s known as the Edwards syndrome. It is a serious cause of mental retardation.
The majority of the children with trisomy 18 present severe cerebral malformations,
severe heart malformations, or severe malformations of other organs. Often, the
growth retardation is found, which can lead to the termination of pregnancy (abor-
tion). Most of the children who are born with the growth retardation die within
their first year of life. Patients who survive present severe intellectual disability and
have problems of growth and development [12].
Trisomy 13 is caused by the presence of an extra chromosome to the 13th pair,
and it’s known as the Patau syndrome. It is a cause of severe mental retardation. The
majority of the patients present serious cerebral and other organs abnormalities. In
many situations the pregnancy doesn’t get to its due date, and the newborn dies
very fast. Half of the born babies die in their first month of life, and 90% from those
who survive in the first year of life present heart malformations, renal
malformations, and renal malformations.
Aneuploidies of the sexual chromosomes are caused by the presence or the
absence of one of the sexual chromosomes. The test can detect the risk for XXX,
XYY, XXYY, and XXY (the Klinefelter Syndrome) and for the X monosomy (the
Turner syndrome). A significant variability exists in regarding the severity of these
genetic conditions, but the majority of the affected individuals are characterized by
slight modifications physically and mentally.
During pregnancy some fragments of the fetal DNA run through the maternal
blood. The fetal DNA is detectable since the 5th week of pregnancy. The concen-
tration increases successively in the next weeks of pregnancy and disappears right
after childbirth. The circulating fetal DNA quantity is found from the 9th to 10th
weeks of pregnancy, and it’s sufficient to guarantee the relevance and the sensibility
of the Panorama Test.
The test is done by collecting a blood sample from the pregnant woman from at
least the 10th week of unique and twin pregnancies. In the laboratory a complex
analysis is made, where the fetal DNA from the maternal blood is isolated. This
procedure identifies the eventual chromosomal abnormalities, like aneuploidy, and
cutting-edge sequencing technology is used, along with advanced bioinformatics
analysis.
The results obtained in the Panorama Test are:
• “High risk” implies that there is a probability that the fetus can present an
aneuploidy of the 21st, 18th, and 13th pairs of chromosomes or an aneuploidy of
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X and Y sexual chromosomes. This result indicates that there is a high chance
that the fetus can present one of the abovementioned abnormalities, but it is
not sure the fetus will have that condition. The endorsed advice is an invasive
prenatal diagnosis test, like chorionic villus biopsy or amniocentesis.
• “Low risk” implies that the test detected a risk <1/10,000 (0.01%) for the fetus
to be affected by a chromosomal aneuploidy.
• In some cases, when the quantity of fetal DNA is not enough, the test can show.
• Incomplete results or no results. In this situation, a new blood sample will be
collected for the repetition of the test. In case the sexual analysis is demanded,
this result can also be provided.
The accuracy of the Panorama Test
The test can detect the risk of a sexual chromosomal aneuploidy with a rate of
detection which varies depending on the type of detected aneuploidy: 13th, 18th,
and 21st.
The test was validated for women with unique and twin pregnancies, with at
least 10 weeks of pregnancy. This test evaluates just the chromosomal aneuploidies
of the 13th, 18th, 21st, X, and Y. In the case of pregnancy with more fetuses,
informations about the sexual chromosomes will not be provided. This procedure
does not replace the invasive prenatal diagnosis (choriocentesis or amniocentesis).
Also, the analysis cannot highlight the equilibrated chromosomal
rearrangements, partial abnormalities of the analyzed chromosomes, structural
chromosome abnormalities, fetal or placental chromosomal mosaicism in a small
percentage (the presence of two cellular lines with a different set of chromosomes,
with a cellular line weakly represented), point mutations, methylation defects, and
polyploidy. In particular, the analysis does not reveal the presence of hereditary
genetic disorders with the Mendelian transmission. The test can give a false-positive
result in the case of chromosomal mosaicism, but this thing can limit itself to the
placenta. The sex of the fetus is mentioned as masculine or feminine, based on the
presence or absence of the Y chromosome, not on the presence or absence of the
SRY gene.
Pregnancies with abnormal ultrasound results should be studied with other
types of prenatal investigations, such as fetal karyotype from the chorionic villi or
amniotic liquid. Although this test is very precise, the results are not a diagnosis,
and they should be evaluated in the clinical context of the patient and the family
medical history. The test is limited to offer just informations about the risks of
aneuploidies for the analyzed chromosomes.
A “low-risk” result can significantly reduce the possibility for the fetus to
present an aneuploidy of the examined chromosomes, but it cannot guarantee that
these chromosomes are normal or that the fetus is healthy.
% diagnosis (sensibility) % false positive ( specificity)
Trisomy 21 (the Down syndrome) 99 (>99%) <0.1% (>99%)
Trisomy 18 (the Edwards syndrome) 99 (>99%) <0.1% (>99%)
Trisomy 13 (the Patau syndrome) 08/10/16 <0.1% (>99%)
Determination of the fetal sex 99 (>99%) <0.1% (>99%)
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This test can be done for 13th, 18th, and 21st aneuploidies also in case of twin
pregnancies and of pregnancies obtained by fertilization in vitro.
This study seeks the degree of accuracy of the prenatal screening which
indicates a high risk. The results are established after the confirmation or informa-
tion of the diagnosis by the invasive diagnosis method for genetical abnormalities,
the amniocentesis procedure. The interventions have been made by the
obstetrician, helped by different doctors, based on the “2 operatives” technique.
The puncture and the extraction of the amniotic liquid will be done by the
obstetrician, and the doctor helping him would monitor by ultrasound the whole
intervention.
Our study is based on a 3-year research (2012–2015). We evaluated 6097
pregnant women, from which 408 had an indication for effectuation of amniocen-
tesis with the purpose of establishing a correct diagnosis. The dynamics of the
number of pregnancies in the analyzed period presents significant decreases from
15%–14.65% in 2014 to 11.15% in 2015.
From the total amount of 408, 114 were made in the year 2012, 102 in the year
2013, 97 in the year 2014, and 95 in the year 2015.
Comparing the dynamics of the number of amniocentesis procedures done in
2015 with the amniocentesis procedures done in 2012, they have a pronounced
decreasing rhythm, so that in 2013 the level decreased by 10.53%, in 2014 the level
decreased by 14.91%, and in 2015 the level decreased by 16.67% due do the appari-
tion of the Panorama Test sampled from the maternal blood.
By the fact that, in medical practice, age above 35 years old in pregnant women
represents a risk factor; the patients have been divided in two groups such as
patients aged until 35 years old and patients above 35 years old.















2012 1641 114 – –
2013 1596 102 97.26 89.47
2014 1402 97 85.44 85.09
2015 1458 95 88.85 83.33
Total 6097 408 – –
Group of age 2012 2013 2014 2015 TOTAL
Under 35 years old 74 66 57 54 251
Above 35 years old 40 36 40 41 157
Total number of patients 114 102 97 95 408
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In the year of our study, 408 amniocentesis procedures have been made. Two
hundred and fifty-one procedures were done on patients with age under 35 years old,
which represents a percentage of 61.5%. One hundred and fifty-seven procedures
were made on patients with age above 35 years old, with a percentage of 38.5%.
The distribution of the patients based on the pregnancy period and the number
of amniocentesis procedures done in percentage:
Even though the number of amniocentesis procedures has slightly decreased, the
number of BI-TESTS has significantly increased since year 2012. In year 2013, the
increasing number has been a percentage of +115.4%, in 2013 it has been +315.45%,
and in the year 2015, it has been 269.2%. In the last 2 years, the percentage for
positive tests for Down syndrome in amniocentesis has been 50%. In all our period
of research, 35.05% of the patients have effectuated the double-positive test for the
Down syndrome.
In the period of our research, the percentage for Down syndrome and Edwards
syndrome of the TRIPLE TEST decreased in relation to the number of amniocente-
sis procedures. In this period the result positive for these tests is considered:
• In 2012 the test for Down syndrome represented 81.58%, and 4.39% for
Edwards syndrome.



















2012 114 93 5 81 4.39
2013 102 64 3 62.75 2.94
2014 97 36 1 37.11 1.03
2015 95 33 1 34.74 1.05
Total 408 226 10 55.39 2.45
Weeks of pregnancy 2012 2013 2014 2015 Total %
Week 15 15 15 14 14 58 14.22
Week 16 36 34 32 39 141 34.56
Week 17 31 28 26 24 109 26.72
Week 18 14 13 IO 8 45 11.03
Week 19 9 5 10 6 30 7.35
Week 20 7 5 3 2 17 4.17
Week 21 2 2 2 2 8 1.96
Total 114 102 97 95 408 100%
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• In 2014 the test for Down syndrome represented 37.11% and 1.03% for the
Edwards syndrome.
Although in 2012 the highest number of amniocentesis procedures (114) was
recorded, a single case was recorded in which amniocentesis had as an indication
the maternal age, which represents a percentage of 0.88%. In 2013, a slight increase
with a percentage of 6.86% is noted (in 2014, 4.12%, and in 2015, 3.16%). In all,
there were 15 procedures made after the indication of the maternal age above 35
years old, with a percentage of 3.68%.
The distribution of the amniocentesis procedures based on priors:
• Down syndrome in the family
• Prior pregnancy with Down syndrome
• Prior pregnancy with Turner syndrome
It is observed that in 2012, from the amount of 114 amniocentesis procedures, 2
of them had as indication the pathological chromosomal history. One of the patients
presents in her family history a member of the family who has Down syndrome.
Another patient had a prior pregnancy with Down syndrome. These indications
represent 1.75% of the indications for year 2012. In 2014 two more pregnant women
have been diagnosed. One of them was coming from a family with Down syndrome,
and the other one had a prior pregnancy with Turner syndrome. These indications
represent a percentage of 2.61% for the year 2014.
From a total of 408 pregnancies, the indications for pathological chromosomal










2012 114 1 1 0
2013 102 0 0 0
2014 97 1 0 1
2015 95 0 0 0
Year Number of amniocentesis procedures Age of the mother >35 Percentage %
2012 114 1 0.88
2013 102 7 6.86
2014 97 4 4.12
2015 95 3 3.16
Total 408 15 3.68
Number of amniocentesis procedures 408 100%
BI-TEST 131 32.10%
TRIPLE TEST 258 63.23%
Indication for maternal age 35 years or above 15 3.67%
66
Modern Medical Genetics and Genomics
From the amount of 408 pregnancies which underwent the amniocentesis pro-
cedure, 149 of them were on their first pregnancy, with a percentage of 36.52%. One
hundred and ninety-eight of the pregnant women were on their second pregnancy
(48.53%), and 61 were on their third or more pregnancy (14.95%).
Distribution of the patients depending on environmental residence
It is concluded that only 23.28% of the pregnant women came from a rural
environment; the rest of 76.72% came from an urban environment.
Distribution of patients depending on chronic diseases
Distribution of patients depending on vicious behavior
It can be observed that, despite the fact that smoking affects the pregnancy and
the fetus, a quite high percentage of pregnant women smoke (39.22%).
Distribution of the patients depending on the result of the amniocentesis
The percentage of Down syndrome reported to the total number of pregnancies
(6097 patients) represents 1.6% above the European statistics. The percentage of
Edwards syndrome reported to the total number of pregnancies represents 0.656%
above the European statistics.
Environment 2012 2013 2014 2015 Total %
Rural 16 34 25 20 95 23.28
Urban 98 68 72 75 313 76.72
Total 114 102 97 95 408 100
Chronic diseases Number of patients %
Diabetes mellitus 11 2.70
Hepatitis A and hepatitis B 5 1.23
High blood pressure 9 2.21
Obesity 10 2.45
Kidney diseases 3 0.74
2012 2013 2014 2015 Total %
Smoker 38 49 36 37 160 39.22
Non-smoker 76 53 61 58 248 60.78
Total 114 102 97 95 408 100
Down syndrome in the family history 2 0.49%
Prior pregnancy with Down syndrome 1 0.24%
Prior pregnancy with Turner syndrome 1 0.24%
Result Number of patients %
Normal results 394 96.57
Down syndrome 10 2.45
Edwards syndrome 4 0.98
Total 408 100
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Maternal ages for women diagnosed with pregnancies with Down syndrome
were 28, 31, 32, 38, and 40 years old.
All the patients with babies diagnosed with Down syndrome or Edwards syn-
drome decided to terminate the pregnancy.
The 14 cases positive for Down syndrome and Edwards syndrome (4 cases
positive for Edwards syndrome and 10 cases positive for Down syndrome) were
actually found because of the indications of the TRIPLE TEST, 4 more cases positive
for Down syndrome were found because of the indications for BI-TEST, and just 1
case of Down syndrome was found because of the indications for maternal age.
Amniocentesis has become the most used prenatal diagnosis method for women
aged 35 and above or even for younger women with a family history specific for
hereditary congenital abnormalities.
In our studied group, 157 pregnant women asked for a prenatal diagnosis for
Down syndrome. They were aged 35 or above 35 and demanded the association of
some pathological biochemical markers (double test, TRIPLE TEST).
The frequency of the structural chromosomal abnormalities (translocations,
deletions, inversions) did not show a similar numeric relationship regarding the
maternal age.
According to the literature, the screening tests have a margin of error in the
diagnosis of fetal malformations, so the diagnosis of certainty will result after the
amniocentesis.
The majority of the specialists consider that amniocentesis is an invasive
procedure, so it is recommended that the number of these procedures should be
decreased. In this regard, our study did very well: the result of the utilization of
the other methods (BI-TEST, TRIPLE TEST) was positive. The BI-TEST
can detect trisomy 21 (the Down syndrome) and trisomy 18 (the Edwards syndrome).
There are tests like Panorama Test which are cutting-edge technology, and they
reduce the use of amniocentesis. But the cost of this test is high and not covered by
the National Health, which is the reason why it is not accessible for all patients.
Our study has been made on a large segment of the population which had access
to all the screening tests (BI-TEST, TRIPLE TEST), but not all of the patients had
this possibility.
The TRIPLE TEST in pregnancy can help in tracking down the neural tube
defects and chromosomal abnormalities such as trisomy 18 and trisomy 21. So, if a
high level of alpha-fetoprotein (AFP gene) is found in the blood, it is likely that the
fetus presents a neural tube defect (more exactly the brain and the spinal cord),
defects such as spina bifida or anencephaly. If the results of the TRIPLE TEST show
a low level of alpha-fetoprotein (AFP gene) and estriol, it can indicate trisomy 21
(the Down syndrome), trisomy 18 (Edwards syndrome), or other chromosomal
abnormalities.
Before we proceeded with the amniocentesis procedure, we acquired from every
patient and her partner a written consent after informing them about what the
procedure implies.
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In obstetrical practice the risk of carrying out an amniocentesis is evaluated
permanently, compared to the individual risk of numerical chromosomal abnor-
malities or structural chromosomal abnormalities. We recommend the amniocente-
sis as an invasive diagnosis prenatal method when the risk of a detectable
abnormality is higher than the risk of the procedure itself.
It is important that the patient should be informed about the pam felt during the
amniocentesis.
Numerical chromosomal abnormalities (aneuploidies)—in the case of amnio-
centesis procedures done to pregnant women with age 35 or above from our con-
signment—have a frequency of 3.18% (5 cases out of 157).
The majority of the patients questioned said that the procedure was a painful
method. Pain is a multidimensional sensation and complex, which varies in quality,
intensity, duration, localization, and inconvenience from an individual to another.
The intensity and inconvenience of the pain is not directly connected to the nature
and the extension of the tissue lesion. Cultural, genetic, familial, growth, psycho-
logical, and social variables have a strong impact in the perception of the pain and in
its expression from the patient.
The objective quantification of the pain is difficult. Before any invasive proce-
dure effectuated throughout pregnancy, the biggest concern of the patient is the
risk and the intensity of the pain during procedures.
Ultrasound conclusions in cases of chromosomal abnormalities
6. Conclusions
In conclusion, all the pregnant women who underwent the amniocentesis pro-
cedure and had a negative result had an on-term pregnancy and delivered healthy
newborn babies.
As for the pregnant women who underwent the amniocentesis procedure and





• Duodenal atresia, tracheoesophageal fistula, and hydramnios are present
usually if there are gastrointestinal damages
• Heart abnormalities—defects of the atrial septum
• Hypoplasia of the middle phalanx of the 5th finger of the hand
• Conclusions from the second trimester: increased cervical skinfold
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• Hydramnios
• Hand wrapped with superimposed fingers (the index covers the third
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• Heart abnormalities: ventricular septal defect
• Omphalocele, diaphragmatic hernia
• Cyst of the choroid plexus
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• Holoprosencephaly (defects of the facial break line)
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patient and her partner a written consent after informing them about what the
procedure implies.
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The purpose of our study was to decrease the use of amniocentesis procedures
and to introduce a cutting-edge technology, which is the Panorama Test for early
diagnosis of fetal malformations. We tried to implement a noninvasive method
(Panorama Test made from the mother’s blood sample) over an invasive method
which is the amniocentesis.
Our purpose has been achieved by the decrease of amniocentesis and by
increasing the use of cutting-edge technology without affecting the final results in
the percentage of the fetal malformations statistics worldwide.
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Do We Have Enough Information?
Tom Nolis and Rodney J. Scott
Abstract
Genomics medicine and molecular genetics are experiencing a surge of interest
as well as a push for a more prominent role in mainstream medicine. This, coupled
with the advancement of next-generation sequencing, along with a national, if not
global, steering of funding to support the advancement and development of genet-
ics is suggesting that we are entering a new age of medicine. As this push begins to
gain some momentum, the impact of genomics medicine on clinical utility and the
influence of supporting data on genes that make their way from research to diag-
nostic medicine are worth reviewing.
Keywords: genetics, genomics, utility, cancer, BRCA1, BRCA2, PALB2, population,
family, epidemiology, multigene, panels
1. Introduction
One of the most fundamental clinical validity and clinical utility questions cur-
rently at the forefront of molecular genetic testing is as important today as it was
nearly 30 years ago, “is the genetic variation detectable in the genes of interest
actually associated with a clear and quantifiable risk for disease?” or in other words,
“are the variants that we are finding in these genes relevant for the disease of
interest?”
The question above is a very important one, and to be able to answer, it we must
take a step back and explore clinical utility and epidemiology in genetics more
thoroughly. The answer to this question requires an inevitable focus on cancer
genetics as breast and ovarian cancer are excellent examples of both past and
present accomplishments in genomics medicine. These disease entities are topical
and have enough data to appropriately highlight the genetic journey previously
taken into genomics medicine, and they are also able to shed light on how new
genetic players are entering the diagnostic scene (e.g., PALB2).
Finally, the following text will briefly compare and contrast the significant
influence of family-based and population studies on genetic data. This chapter will
close on a more general note by reviewing the current cancer assessment guidelines





Do We Have Enough Information?
Tom Nolis and Rodney J. Scott
Abstract
Genomics medicine and molecular genetics are experiencing a surge of interest
as well as a push for a more prominent role in mainstream medicine. This, coupled
with the advancement of next-generation sequencing, along with a national, if not
global, steering of funding to support the advancement and development of genet-
ics is suggesting that we are entering a new age of medicine. As this push begins to
gain some momentum, the impact of genomics medicine on clinical utility and the
influence of supporting data on genes that make their way from research to diag-
nostic medicine are worth reviewing.
Keywords: genetics, genomics, utility, cancer, BRCA1, BRCA2, PALB2, population,
family, epidemiology, multigene, panels
1. Introduction
One of the most fundamental clinical validity and clinical utility questions cur-
rently at the forefront of molecular genetic testing is as important today as it was
nearly 30 years ago, “is the genetic variation detectable in the genes of interest
actually associated with a clear and quantifiable risk for disease?” or in other words,
“are the variants that we are finding in these genes relevant for the disease of
interest?”
The question above is a very important one, and to be able to answer, it we must
take a step back and explore clinical utility and epidemiology in genetics more
thoroughly. The answer to this question requires an inevitable focus on cancer
genetics as breast and ovarian cancer are excellent examples of both past and
present accomplishments in genomics medicine. These disease entities are topical
and have enough data to appropriately highlight the genetic journey previously
taken into genomics medicine, and they are also able to shed light on how new
genetic players are entering the diagnostic scene (e.g., PALB2).
Finally, the following text will briefly compare and contrast the significant
influence of family-based and population studies on genetic data. This chapter will
close on a more general note by reviewing the current cancer assessment guidelines
and how these reflect the current clinical utility of genomics medicine.
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1.1 Key points
• Clinical utility in genetics is largely a continual revamp of the ACCE
framework.
• Genetic epidemiology has followed a natural flow paralleling the advancement
of technology and detection.
• Family-based studies and population data are still at the forefront of both
research genetics and diagnostic genomics.
• BRCA1 and BRCA2 are excellent models for useful genetics input.
◦ This has led to a complete change in the identification and treatment
of a very tangible cancer entity.
• Less penetrant genes in breast and ovarian cancer, such as PALB2, along with
multigene panels have their place in genomics medicine, but, generally, quality
supportive data are lacking.
2. Clinical utility in genetic testing
Clinical utility is a broad concept and one that is deeply fundamental in the
world of medicine. At its most basic level, it is the essence of what propels medical
advancement. It answers the question of “what should I do next?” when this ques-
tion is asked by physicians, but it can also be a much larger almost all encompassing
concept; as if to ask, “what is worth doing next?” in any field of medicine. Clinical
utility, by many sources, can be simply defined as “the balance of benefits to risks”
or more broadly refer to any use of test results to inform clinical decision-making
[1]. A genetic test can be defined as a “test that involves the analysis of chromo-
somes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), genes, or gene prod-
ucts (e.g., enzymes and other proteins) to detect heritable or somatic variations
related to disease or health. Whether a laboratory method is considered a genetic
test also depends on the intended use, claim or purpose of a test” [2].
In some fields, such as in colorectal surgery, it is easy to determine clinical
utility: if the patient’s morbidity or mortality is improved by removing a tumor,
then you remove it; otherwise you do not. In the realm of genetic testing, the
concept of clinical utility can be difficult to precisely define—or even quantify.
Indeed, this was reinforced when experts in evidence-based medicine and genetics
for the Centers for Disease Control and Prevention (CDC) in 2005 failed to come to
a consensus on the term “clinical utility” despite initially claiming to be confident in
its meaning beforehand [1]. As a consequence, the term had to be elaborated on by
the Analytic validity, Clinical validity, Clinical utility, and Ethical, legal and social
implications (ACCE) project that was carried out by the Foundation for Blood
Research with support from the CDC [1]. In screening or in diagnostic testing,
clinical utility broadly refers to the ability of a test to prevent or ameliorate adverse
health outcomes such as mortality, morbidity, or disability through the adoption of
efficacious treatments conditioned on test results (Figure 1) [1]. The perceived
value of genotypic information, at this point in time, includes a more thorough
understanding of a patient’s diagnosis, prognosis, risk, and disease or treatment
susceptibility; the caveat is that this knowledge may not influence clinical manage-
ment at all. Clinical utility in the ACCE framework was expanded to include
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contextual or implementation issues (e.g., availability of resources) and that clinical
utility can also include psychological benefits.
2.1 Evaluating genetic tests
Evaluating genetic tests is often methodologically difficult largely due to small
patient populations and the resulting dearth of high-quality studies. Adapted from
Morrison et al. 2012, the following subsections are generally agreed upon as com-
mon characteristics for reviewing genetic tests [3, 4].
2.1.1 Overview of disease and underlying genetics
• Information on the disease prevalence, treatments, and outcomes of the disease
as well as overall cost
• Description of the genetic causes, including inheritance patterns
• Classifying the mutational spectrum, along with the prevalence and penetrance
• Determination if there is any “gold standard” tests to compare to
2.1.2 Target population and intended use
• Prevalence for target population involves age, ethnicity, and eligibility for
testing
Figure 1.
Clinical utility in genetics. The clinical utility in screening tests is to provide preventative care and to improve
primary end points such as overall morbidity; in a diagnostic setting, the value of genetic testing lies in the
balance of benefits to risks in more psychological domains.
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• Purpose of the test: is it diagnostic, for treatment, prognosis, management,
carrier testing, prenatal testing, or other?
2.1.3 Laboratory information
• Validation details
◦ Test new or already in use?
▪ If already in use:
• Number and rate of positive and negative mutations
• Turn-around-time for results
• Similar tests available
• Current testing activity and expected with appropriate funding
figures
• Whether there are other laboratories that could offer the test
• Infrastructure requirements
• Quality assurance, maintenance, and improvement programs—both internally
and externally
2.1.4 Economic considerations
• Cost estimates for the test including equipment, personnel, and consumables/
reagents
• Costs of disease burden with or without treatment
• Costs saved by employing test
2.1.5 Analytic validity
• Precision, reliability, accuracy, sensitivity, and specificity of the genetic test,
and how these compare with other employed screening and diagnostic tests
2.1.6 Clinical validity
• Specificity and sensitivity, positive predictive value, negative predictive value,
likelihood ratios, and how these compare with other employed screening and
diagnostic tests
2.1.7 Clinical utility
• Benefits and risks of the test
• Treatment of the patient
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• Patient’s health outcome
• Effect on patient and patient’s family members
• Alternative diagnostic tests compare and contrast to genetic testing
2.1.8 Ethical, legal, and social
• Details on ethical, legal, and societal issues include support and follow-up
2.2 ACCE model and beyond
The CDC furthered the ACCE framework by establishing the Evaluation of
Genomic Applications in Practice and Prevention (EGAPP) Initiative. The EGAPP
supports the development and implementation of an evidence-based process for
evaluating genetic tests and other genomic applications for clinical and public health
practice. An independent, nonfederal EGAPPWorking Group (EWG), consisting of
a multidisciplinary expert panel selects topics of interest, reviews evidence, and
recommends courses of action [2]. Key objectives of the EWG are to develop an
openly accountable process, reduce conflicts of interest, and provide a connection
between well-established evidence and the EWG recommendations [2, 5].
The ACCE model has stood the test of time and has proven to be a basis for the
technical appraisal of genetic tests across the globe (Figure 2). The UK Genetic
Testing Network and the Andalusian Agency for Health Technology Assessment
expanded the ACCE model to guide the introduction of new genetic tests into their
Figure 2.
Genetic testing appraisal frameworks. Testing appraisal frameworks around the globe have largely stemmed
from the analytic validity, clinical validity, clinical utility, and ethical, legal and social implications (ACCE)
framework announced in 2000. EGAPP, evaluation of genomic applications in practice and prevention; ECRI,
Emergency Care Research Institute; NHS UKGTN, National Health Service UK Genetic Testing Network;
CAT, companion test assessment; GFH, German Society of Human Genetics.
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public health system, creating the 2004 NHS UKGTN Gene Dossier and the 2006
Andalusian Framework. In 2007, the ACCE model was again modified by adding
health quality measures to the evaluation process. The process was made more
streamlined, shortening the systematic review process for emerging genetic tests. In
2010, the ACCE model was adapted to particular types of genetic testing through
the Complex Disease Framework and the ACHDNC Newborn Screening Frame-
work of the Advisory Committee on Heritable Disorders in Newborns and Children.
The ACCE model also spawned two European frameworks: the 2008 GFH Indica-
tion Criteria of the German Society of Human Genetics and the 2010 Clinical Utility
Gene Card of EuroGentest. The 2015 Companion test Assessment Tool (CAT) build
upon the ACCE model to determine which tests needed further evaluation. In 2011,
the ECRI Institute utilized the EGAPP process to develop a set of analytical frame-
works for various testing scenarios and other stakeholder aspects. Lastly, the
EuroGentest inspired the 2017 Australian Clinical Utility Card [5].
We cannot ignore the influence of the stakeholders who will invariably have
wildly different opinions as to which outcomes are considered relevant. Thus, the
types of outcomes that must be considered in evaluating the utility of a genetic test
will also depend on the purpose of the test and the congregation of those who make
the final decision. For example, a state-funded public health program will likely
focus on the overall impact on morbidity and mortality versus privately funded
sectors concentrating on the greater net profit. Coverage decisions by third-party
payers may be based in large part on perceptions that test results are useful for
timely or accurate diagnoses and clinical management. For a test that is offered to
families in a clinical setting on a voluntary basis, the value of information for
making career, residential, and reproductive decisions take on greater relevance.
Before a genetic test can be accepted into clinical practice, data must be collected
to demonstrate the benefits and risks that accumulate from both positive and
negative results [1]. Referring back to the colorectal surgery example above, the
term “clinical utility” fits in very well; however, when applied to genetics or geno-
mics medicine, the term may be too limited. The clinical end points are extremely
important, but the utility or actionable context must remain broad in genetics to
embody an overall net benefit. Genetic testing is particularly useful in the psycho-
social, ethical, legal, and social (ELS) realms as well as in many diagnostic cases
(Figure 1). By including clinical and ELS together in the concept, improvements in
health outcomes such as enhancements in morbidity, mortality, and in disability
become strong primary end points when assessing the utility of genetic testing.
3. Genetic epidemiology: population and family-based studies
The process of genetic epidemiology has flowed sequentially from observing
phenotypic differences between populations to demonstrating that diseases can run
in families, to examining feasible genetic susceptibility models, to tracking co-
segregating genetic markers with disease in families, to narrowing the region of
candidate genes, to association analyses with candidate genes, to cloning and muta-
tion identification, to functional and structural characterization of a gene, and,
ultimately, to extending the phenotype characterization even further based on the
genotype identified (Figure 3) [6].
Population and family-based studies are at the heart of genetic epidemiology.
Population-based association studies are generally regarded as more statistically
powerful than family-based studies, as they tend to have more subjects and are
overall easier to execute [6]. Family-based designs are influential methods that use
the proband as well as their relatives to assess the genetic and molecular
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epidemiology of disease (Figure 4). The various types of studies available include
familial aggregation, twins, segregation, linkage, and association.
Linkage and association studies directly evaluate genetic markers and require
the collection of DNA from the study subjects—as opposed to twin studies,
segregation studies, and familial aggregations studies. Family-based studies have
been the long-standing primary approach to detect disease-causing genes.
Segregation and linkage studies are highly valuable methods for assisting in
Figure 3.
Genetic epidemiological historical progression.
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cloning highly penetrant rare disease-causing genes. Family-based association
studies strengths lie in their ability to control for confounding bias due to popula-
tion stratification—albeit they do so at a loss of power [1, 5, 6].
Population stratification is when contrived associations can be detected if cases
and controls come from different source populations that have systematic differ-
ences in ancestral allele frequencies. A great advantage of employing family-based
study designs is that population stratification can be circumvented. By studying
parents and their offspring/siblings, cases and controls within each family are
virtually guaranteed to arise from the same sample source or population. Due to the
increasing efficacy of identification of association with disease, the importance of
family-based studies has seemingly subsided; however, it is worth pressing that
family-based studies are arguably more important than they have ever been as they
are still the only way to truly link a causative variant to disease [1, 5, 6].
Family-based studies can help determine whether a disease or trait is genetically
influential by studying familial aggregation. Results can be furthered with a segre-
gation analysis to identify the mode of inheritance. The results from the segregation
analysis can add power to a linkage analysis, which searches across the entire
genome in an attempt to locate regions containing causal genes [1, 5, 6].
Segregation analysis is a method of establishing the genetic inheritance of dis-
ease and is performed exclusively with family data. This approach assists in
Figure 4.
A closer look at family-based and population studies.
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determining if a disease segregates with a variant in a single gene; in addition to
this, the mode of inheritance can also be ascertained. Very large pedigrees and
families with a plethora of affected individuals are exceptionally informative for
identifying specific genes [1, 5, 6].
Once a family is collected, and studied, in a segregation analysis, that family is
generally made available for further analyses (e.g., linkage). Linkage occurs when
two loci/alleles on the same chromosome are inherited together. Since recombination
during meiosis can occur virtually anywhere in the genome it stands to reason
that the closer two loci are to each other the less likely they will be separated after
a recombining event (i.e., the more likely they are to stay together after recombina-
tion), that is, it says they are “linked.” Linkage analyses utilize this phenomenon
by investigating co-segregating genetic markers along with a disease trait seen within
the family (or families)—the trait can be either qualitative or quantitative. If the
markers and traits are observed to co-segregate within families, it can be logically
inferred that the disease-causing variants are within close proximity to the markers
[1, 5, 6].
This point reveals that linkage is “intrafamilial,” whereby the co-segregating
marker allele may very well be different in different families. Families are generally
recruited into linkage studies on the basis of having at least one identified affected
individual, and the families are either quite large or have affected siblings. Gener-
ally, the markers are spaced evenly over the entire genome, and linkage can be
performed by utilizing these markers.
4. Breast and ovarian cancer: the journey of finding BRCA1 and BRCA2
Establishing penetrance is an arduous undertaking even for some of the most
well-studied genes (e.g., with BRCA1 and BRCA2) simply because no two genetic
studies have yielded the same findings. Many of the data and results discrepancies
can be linked to differences in the populations studied and to the methodologies
employed. It is vanishingly rare, if not impossible, for these studies to have similar
methodologies to allow for perfect reproduction of results. The range of penetrance
found for the BRCA variants and genes has guided the clinical recommendations for
breast and ovarian cancer surveillance and prevention and has provided a sort of
genetic “gold standard” by which all other genes are now compared and contrasted
against [7, 8].
A strong family history of breast cancer is associated with an early age of onset,
the addition of ovarian cancer, bilateral tumors, and a rarely affected male. BRCA1
(and similarly for BRCA2) has been identified through the study of women who
have presented with a strong family history of breast and ovarian cancer (Figure 5).
In 1988, more than 1500 families with multiple cases of breast and ovarian cancer
were studied; the data generated was subjected to a segregation analysis. The results
illuminated that roughly 5% of cases, particularly those with early-onset disease,
could be heritable in a Mendelian fashion. Selected families, those with near-
Mendelian pedigree patterns, were aggregated for linkage analysis. A major suscep-
tibility locus, BRCA1 (OMIM 113705), was mapped to 17q21 in 1990. 17q-linked
families that were above 45 years of age at diagnosis were given negative LOD
scores.
In 1994, a linkage analysis performed on 15 large families with breast cancer that
were also determined to not be linked to 17q helped identify the BRCA2 locus
located on 13q12 (OMIM 600185). Later that year BRCA1 was cloned, and in 1995
BRCA2 was cloned. BRCA1 variants accounted for a very large proportion of
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families with both breast and ovarian cancers, while male breast cancer was pre-
dominately observed in BRCA2 variant families [9].
BRCA1 and BRCA2 were identified by focusing on a small number of specific
families. Other candidate genes were established from focused studies.
• In 2004, the variant c.1100de1C in the CHEK2 gene was observed in 201 cases
(1.9%) and 64 controls (0.7%) in 10,860 breast cancer cases and 9065 controls
from 10 case-control studies in 5 countries (estimated odds ratio (OR) 2.34;
95% CI 1.72–3.20; P = 0.0000001) [10].
• In 2006, the ATM gene was screened in individuals from specific families, and
12 mutations were found in affected individuals and in 2 controls (P = 0.0047)
from 443 familial breast cancer pedigrees and 521 controls (estimated relative
risk of 2.37 (95% CI 1.51–3.78, P = 0.0003) [11].
Figure 5.
The progression of discovering the BRCA1 gene.
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• BRIP1 was initially described as a breast cancer predisposition gene in 2006.
The analysis of 1212 women with familial breast cancer along with 2081
controls yielded mutations in 9 cases and in 2 controls (estimated relative risk
of 2.0; 95% CI = 1.2–3.2; P = 0.012) [12].
• PALB2 mutations were found in 10 cases of 923 individuals with familial
breast cancer, and no mutations were found in 1084 controls (P = 0.0004)
(estimated odd ratio of 2.3; 95% CI = 1.4–3.9; P = 0.0025) [13].
These factors are the most relevant in families where the disease and the
variant are actually segregating together, but at a population level, their overall
implication is surprisingly small. For instance, CHEK2:c.1100de1C, at a population
level, is seen in only 1.9% of cases [14].
5. Less penetrant genes: PALB2, BRIP1, and RECQL
Traditionally, epidemiological studies tend to emphasize the inclination that the
greatest benefits to the population are found in interventions that decrease risk
factors for the bulk of the population, not in targeting a small number of individuals
at the extreme ends of the risk spectrum. As we can see from the sample multigene
panel for hereditary breast cancer the genes selected for testing range from quite
influential (e.g., BRCA1 and BRCA2) to marginally influential (e.g., STK11)
(Table 1). However, it is quite interesting to explore the data for lower-risk genes
such as PALB2 and BRIP1 and also for genes that are suspected of having involve-
ment in breast or ovarian cancer, but the data is not quite yet congruent with the
theory (e.g., RECQL).
Less penetrant genetic loci are mainly represented by the single-nucleotide
polymorphisms (SNPs) or by the variants of uncertain significance discovered
through genome-wide association studies. Variants associated with a minor
increased risk, unlike high-risk mutations, can only account for a small portion of
cancers seen in family histories of carriers. Thus, the cumulative risk for carriers
with a positive family history will largely depend on the risk levels attributed to
both their family history for that cancer and the risk induced by the variant itself.
For example, if a carrier of a variant associated with an increased odds ratio of
cancer also has a family history sufficient to quadruple her risk, her cumulative risk
will be about that of a woman with a 4 x OR increased risk [7].
Mutations in ATM, PALB2, and CHEK2:c.1100delC, in conjunction with a
strong family history, are very likely to be associated with a high absolute risk
of breast cancer [17]. It is important to note that the family history creates a
context whereby it changes the penetrance of these mutations. This interpreta-
tion is clinically important and would justify testing for these mutations in
multi-case breast cancer families such as those seen by typical cancer family
genetics services.
Genetic risk factors, which are familial by their very definition, will be more
frequent in women with positive family histories involving multiple breast cancers
through their direct association with breast cancer as a disease entity and with their
direct association with the familial aspect of breast cancer. This can be illustrated in
a simple example where we consider a rare mutation whose presence doubles the
risk of breast cancer relative to the general population: it will be roughly four times
more common in women who are affected and who have an affected first-degree
relative, which will square the ratio [17].
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5.1 PALB2
The Finnish founder mutation was found in 0.9% (18 of 1918) of cases without
selecting for or emphasizing family history. Likewise, a French-Canadian founder
mutation was found in 0.6% (2 of 356) of cases also without selecting for or
emphasizing family history selected. The numbers of the PALB2 founder mutation
carriers were too small to make precise risk inferences, but modified segregation
analyses of data from the families of case-carriers were used to estimate risk for
carrier families, which has demonstrated the importance of these founder muta-
tions in the risk of developing breast cancer [13, 14, 18, 19].
Blanco et al. found that the frequency of PALB2 mutations was 1.5% after
investigating the incidence of mutations in PALB2 patients with breast cancer that
were also negative for any variants in BRCA1 and BRCA2 +/ a family history of
pancreatic cancer; previous studies had the mutation rate for similar cohorts range
from 0 to 4.8%. Dansonka-Mieszkowska et al. conducted similar research among
Polish women; their study showed a minor but significant PALB2 mutation pres-
ence at 0.6% [13, 14, 18, 19].
Sample multigene hereditary breast cancer panel
Gene Notes
ATM c.7271 T > G —
other ATM
mutations
Lack of data regarding penetrance and surveillance except for c.7171 T > G
mutation. If mutation has been identified, a careful assessment of residual risk for





CDH1 Increased risk of lobular breast cancer. Gastric cancer risk is unknown when
mutations are identified in absence of a positive family history of gastric cancer
CHEK2
c.1100delC
Mutations are rare, but high penetrance in some families
other CHEK2
mutations
Lack of penetrance data except for in specific mutations
NBN —
NF1 Can identify mutation carriers by clinical phenotype and then perform gene
specific test




PTEN Can usually be identified by clinical phenotype
RAD50 —
STK11 Can usually be identified by clinical phenotype. Low penetrance in breast cancer
TP53 Breast cancer risk management inferred from other genes. High penetrance for
breast cancer, but mutations are rare
Adapted from: Invitae and eviQ [15, 16].
Table 1.
Sample multigene panel offered for hereditary breast cancer.
86
Modern Medical Genetics and Genomics
Likewise, Bogdanov et al. conducted a study on the occurrence of PALB2 muta-
tions among Russian and German women and reported a mutation rate of 2%. In
2014, Antoniou et al. tested 362 women from 154 families and found that the risk of
breast cancer in women 40 years of age or younger with PALB2 mutation was 9x
greater, 8x greater in patients aged 40–60 years, and 5x greater in patients
60 years and older when compared to the general population. The absolute risk of
breast cancer in women with PALB2 mutations under 70 years of age ranges from
33 to 58% for women without and with a positive family history of breast cancer,
respectively. Interestingly, Hartley et al. conducted a study that confirmed that as
the number of cases of breast cancer in a family increases, the likelihood of PALB2
mutations increases as well. Women with 3+ positive cases of familial breast cancer
have a 2.6% greater likelihood of having a PALB2 mutation than those without
multiple cases [13, 14, 18, 19].
Southley et al. studied Australian women to determine the occurrence rate and
penetrance of PALB2 mutations. The study found that the women with breast
cancer and a positive family history of having PALB2 mutations had PALB2 muta-
tions present in 1% of patients. The study identified that the women with breast
cancer and no family history of PALB2 mutations had PALB2 mutations present in
only 0.4% of patients. There were no PALB2 mutations detected in the control/
healthy population of women. Heikkinen et al. studied southern Finnish women
and found PALB2 mutations in 2% of patients with a positive familial history of
breast cancer and also in 0.6% of women with a sporadic breast cancer presentation
[13, 14, 18, 19].
In 2016, a seminal paper by Thompson et al. examined 2000 predominantly
breast cancer-affected women with a strong family history that were also BRCA1
and BRCA2 variant-negative and compared them to 1997 controls. They observed
that a significant proportion of mutations were only in PALB2 (26 cases vs. 4
controls) and in TP53 (5 cases vs. none in controls), whereas no mutations were
identified in STK11 [14]. PALB2 is a great example of how penetrance estimates can
depend on the population, family history, and age at onset as well as other consid-
erations [17].
5.2 BRIP1
BRIP1 was initially described as a breast cancer predisposition gene in 2006.
The analysis of 1212 women with familial breast cancer along with 2081 controls
yielded mutations in 9 cases and in 2 controls (estimated relative risk of 2.0; 95%
CI = 1.2–3.2; P = 0.012). However, recently BRIP1’s association with breast cancer
has grown suspect, while its association with ovarian cancer has risen sharply.
BRIP1 mutations confer a high ovarian risk in familial index patients (OR = 20.97,
95% CI = 12.02–36.57; P < 0.0001) and in the subgroup of patients with late onset
ovarian cancer (OR = 29.91, 95% CI = 14.99–59.66; P < 0.0001) [12].
5.3 RECQL
In a screen of 144 Polish and 51 French-Canadian women with early-onset
familial breast cancer, 2.6% possessed truncating mutations in RECQL. Validation
studies that reviewed the RECQL variant c.1667_1667C3delAGTA in over 13,000
breast cancer patients with 4702 Polish controls showed the RECQL mutation
appeared in 0.23% of cases and in 0.04% in controls. Likewise, the RECQL variant
c.634C > T (p. Arg215*) seen in the French-Canadian population was further
screened in 538 patients and 7136 newborn controls and was detected in 5 patients
and in one control—a nearly 50x increase in frequency in affected versus
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pancreatic cancer; previous studies had the mutation rate for similar cohorts range
from 0 to 4.8%. Dansonka-Mieszkowska et al. conducted similar research among
Polish women; their study showed a minor but significant PALB2 mutation pres-
ence at 0.6% [13, 14, 18, 19].
Sample multigene hereditary breast cancer panel
Gene Notes
ATM c.7271 T > G —
other ATM
mutations
Lack of data regarding penetrance and surveillance except for c.7171 T > G
mutation. If mutation has been identified, a careful assessment of residual risk for





CDH1 Increased risk of lobular breast cancer. Gastric cancer risk is unknown when
mutations are identified in absence of a positive family history of gastric cancer
CHEK2
c.1100delC
Mutations are rare, but high penetrance in some families
other CHEK2
mutations
Lack of penetrance data except for in specific mutations
NBN —
NF1 Can identify mutation carriers by clinical phenotype and then perform gene
specific test




PTEN Can usually be identified by clinical phenotype
RAD50 —
STK11 Can usually be identified by clinical phenotype. Low penetrance in breast cancer
TP53 Breast cancer risk management inferred from other genes. High penetrance for
breast cancer, but mutations are rare
Adapted from: Invitae and eviQ [15, 16].
Table 1.
Sample multigene panel offered for hereditary breast cancer.
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Likewise, Bogdanov et al. conducted a study on the occurrence of PALB2 muta-
tions among Russian and German women and reported a mutation rate of 2%. In
2014, Antoniou et al. tested 362 women from 154 families and found that the risk of
breast cancer in women 40 years of age or younger with PALB2 mutation was 9x
greater, 8x greater in patients aged 40–60 years, and 5x greater in patients
60 years and older when compared to the general population. The absolute risk of
breast cancer in women with PALB2 mutations under 70 years of age ranges from
33 to 58% for women without and with a positive family history of breast cancer,
respectively. Interestingly, Hartley et al. conducted a study that confirmed that as
the number of cases of breast cancer in a family increases, the likelihood of PALB2
mutations increases as well. Women with 3+ positive cases of familial breast cancer
have a 2.6% greater likelihood of having a PALB2 mutation than those without
multiple cases [13, 14, 18, 19].
Southley et al. studied Australian women to determine the occurrence rate and
penetrance of PALB2 mutations. The study found that the women with breast
cancer and a positive family history of having PALB2 mutations had PALB2 muta-
tions present in 1% of patients. The study identified that the women with breast
cancer and no family history of PALB2 mutations had PALB2 mutations present in
only 0.4% of patients. There were no PALB2 mutations detected in the control/
healthy population of women. Heikkinen et al. studied southern Finnish women
and found PALB2 mutations in 2% of patients with a positive familial history of
breast cancer and also in 0.6% of women with a sporadic breast cancer presentation
[13, 14, 18, 19].
In 2016, a seminal paper by Thompson et al. examined 2000 predominantly
breast cancer-affected women with a strong family history that were also BRCA1
and BRCA2 variant-negative and compared them to 1997 controls. They observed
that a significant proportion of mutations were only in PALB2 (26 cases vs. 4
controls) and in TP53 (5 cases vs. none in controls), whereas no mutations were
identified in STK11 [14]. PALB2 is a great example of how penetrance estimates can
depend on the population, family history, and age at onset as well as other consid-
erations [17].
5.2 BRIP1
BRIP1 was initially described as a breast cancer predisposition gene in 2006.
The analysis of 1212 women with familial breast cancer along with 2081 controls
yielded mutations in 9 cases and in 2 controls (estimated relative risk of 2.0; 95%
CI = 1.2–3.2; P = 0.012). However, recently BRIP1’s association with breast cancer
has grown suspect, while its association with ovarian cancer has risen sharply.
BRIP1 mutations confer a high ovarian risk in familial index patients (OR = 20.97,
95% CI = 12.02–36.57; P < 0.0001) and in the subgroup of patients with late onset
ovarian cancer (OR = 29.91, 95% CI = 14.99–59.66; P < 0.0001) [12].
5.3 RECQL
In a screen of 144 Polish and 51 French-Canadian women with early-onset
familial breast cancer, 2.6% possessed truncating mutations in RECQL. Validation
studies that reviewed the RECQL variant c.1667_1667C3delAGTA in over 13,000
breast cancer patients with 4702 Polish controls showed the RECQL mutation
appeared in 0.23% of cases and in 0.04% in controls. Likewise, the RECQL variant
c.634C > T (p. Arg215*) seen in the French-Canadian population was further
screened in 538 patients and 7136 newborn controls and was detected in 5 patients
and in one control—a nearly 50x increase in frequency in affected versus
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unaffected individuals. Studies of patients in northern China revealed a patho-
genic RECQL mutation in 2.0% of the 448 familial breast cancer patients com-
pared to the 0.06% seen in 1588 control subjects [20]. By whole exome sequencing
0 early-onset familial breast cancer patients without BRCA1/2 mutations and by
screening the RECQL gene in an additional 439 unrelated familial breast cancer
patients, 9 index cases were found to carry a pathogenic mutation in the RECQL
gene among the 448 BRCA-negative familial breast cancer patients. It was deter-
mined that the pathogenic mutation rate of the RECQL gene in familial breast
cancer in BRCA1-/BRCA2-negative breast cancer patients was 2.0%. Further to
these results, no loss of heterozygosity was found in the RECQLmutation carriers,
suggesting that RECQL-associated tumorigenesis is likely through classical
haploinsufficiency [21].
In 2018, Li et al. sequenced all the exons of RECQL and at least 10 bp of the
exon–intron flanking regions in 9112 subjects from Australia. The case subjects
were females diagnosed with breast or ovarian cancer from 4536 families with a
negative result after BRCA1 and BRCA2 mutation testing. The controls were 4576
women who were above 40 years of age and were cancer-free as of May 2016.
Thirteen loss-of-function mutations in the cases and 25 in the controls were
identified (0.29 versus 0.55%, odds ratio 0.52, 95% confidence interval 0.25–1.06,
P = 0.072 by two-tailed Fisher’s exact test) [22]. Missense variants observed
between cases and controls were not statistically significant (54 cases, 1.19%,
versus 37 controls, 0.81%; P = 0.073) [22]. It is generally accepted that a predis-
position gene is considered actionable only if the 90% confidence limit of the
estimated relative risk is greater than four [22]; therefore, RECQL, can be
excluded based on these findings.
5.4 Lack of data and the impact of finding a variant of unknown significance
Despite the intense and widespread shared enthusiasm to reduce the risk of
predictable cancers, the adoption of the more recent breast cancer predisposition
genes, such as PALB2, has been sluggish. This has been largely due to the com-
munal appreciation that following a variant of unknown significance result, the
complexity of interpretation may lead to a subsequent clinical utility hindrance.
An additional 3.9% of patients tested by multiple gene panels had pathogenic
mutations identified in other breast cancer predisposition genes, namely, in
PALB2, CHEK2, and ATM; however, many of these multigene panel tests also
identified many variants of uncertain significance, where the classification is
either uncertain or simply just not possible—and this information cannot safely be
utilized clinically [19].
Indeed, this consideration is shared in recent literature and has been extended
by Thompson et al. where the authors examined various genes that are common on
hereditary breast cancer panels. They observed that the frequency of mutations in
most breast cancer panel genes is quite low, or even, in most cases, similar to the
frequency of mutations observed in cancer-free population controls. They con-
cluded that panels have the potential to provide clinical misinformation and harm at
the individual level if the data is not interpreted with extreme caution [14]. This
lack of evidence for new genetic players is not limited to breast and ovarian cancer,
but it also plagues many other genetic diseases and also afflicts a great number of
other multigene panels [19].
Due to this lack of supportive data, international large-scale studies into the
genes included in these multigene panels are absolutely critical to increase the
utility of the information yielded and also to ensure that the new genetic informa-
tion presented is both safe and useful in a clinical setting.
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6. Conclusions
Keeping in-line with global regulation entities such as CAT, EGAPP, NHS
UKGTN, and the ACCE backbone discussed above, the recent initiative eviQ pro-
vides a variety of guidelines for cancer genetics investigations. EviQ is part of the
Cancer Institute NSW (New South Wales) and provides evidence-based informa-
tion to support health professionals in the delivery of cancer treatments available at
the time treatment decisions are being made. We can see from the eviQ’s general
practitioner referral guidelines for cancer genetics assessment that generally, even
in oncology, genetics plays a large part in the diagnostics of disease [23]. We can
also note that there must be a strong clinical suspicion of the diagnosis involving a
genetic element (e.g., quite young, strong family history, hailing from a region with
restricted gene flow, etc.) to warrant testing and for it to be useful.
The clinical utility of genetics is highly variable and dependent on the gene or
disorder involved, but genomics medicine appears to be very good at revealing a
diagnosis, and, at times, it can help explain why the phenotype is the way it is. In
oncology, genetic testing plays an integral role in disease management by influenc-
ing treatment options or by being a major inclusion component for clinical trials.
Where genetic testing is taking off and, perhaps, where its true potential lies is in its
ability to offer predictive and preventative medicine, particularly for families, as
opposed to adhering to a purely reactive approach that is typically employed in
mainstream medicine.
Genomics is by no means irrelevant; it is revealing much about human disease
and pathophysiology, but barring the current leaps and bounds observed in oncol-
ogy, genomics medicine is still in an informational gathering phase—albeit, it is
doing so at an alarming and unparalleled rate. It will take a great deal more data,
analysis, and time before it will be considered true mainstream medicine, but there
is no doubt that genomics is the future of medicine.
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pared to the 0.06% seen in 1588 control subjects [20]. By whole exome sequencing
0 early-onset familial breast cancer patients without BRCA1/2 mutations and by
screening the RECQL gene in an additional 439 unrelated familial breast cancer
patients, 9 index cases were found to carry a pathogenic mutation in the RECQL
gene among the 448 BRCA-negative familial breast cancer patients. It was deter-
mined that the pathogenic mutation rate of the RECQL gene in familial breast
cancer in BRCA1-/BRCA2-negative breast cancer patients was 2.0%. Further to
these results, no loss of heterozygosity was found in the RECQLmutation carriers,
suggesting that RECQL-associated tumorigenesis is likely through classical
haploinsufficiency [21].
In 2018, Li et al. sequenced all the exons of RECQL and at least 10 bp of the
exon–intron flanking regions in 9112 subjects from Australia. The case subjects
were females diagnosed with breast or ovarian cancer from 4536 families with a
negative result after BRCA1 and BRCA2 mutation testing. The controls were 4576
women who were above 40 years of age and were cancer-free as of May 2016.
Thirteen loss-of-function mutations in the cases and 25 in the controls were
identified (0.29 versus 0.55%, odds ratio 0.52, 95% confidence interval 0.25–1.06,
P = 0.072 by two-tailed Fisher’s exact test) [22]. Missense variants observed
between cases and controls were not statistically significant (54 cases, 1.19%,
versus 37 controls, 0.81%; P = 0.073) [22]. It is generally accepted that a predis-
position gene is considered actionable only if the 90% confidence limit of the
estimated relative risk is greater than four [22]; therefore, RECQL, can be
excluded based on these findings.
5.4 Lack of data and the impact of finding a variant of unknown significance
Despite the intense and widespread shared enthusiasm to reduce the risk of
predictable cancers, the adoption of the more recent breast cancer predisposition
genes, such as PALB2, has been sluggish. This has been largely due to the com-
munal appreciation that following a variant of unknown significance result, the
complexity of interpretation may lead to a subsequent clinical utility hindrance.
An additional 3.9% of patients tested by multiple gene panels had pathogenic
mutations identified in other breast cancer predisposition genes, namely, in
PALB2, CHEK2, and ATM; however, many of these multigene panel tests also
identified many variants of uncertain significance, where the classification is
either uncertain or simply just not possible—and this information cannot safely be
utilized clinically [19].
Indeed, this consideration is shared in recent literature and has been extended
by Thompson et al. where the authors examined various genes that are common on
hereditary breast cancer panels. They observed that the frequency of mutations in
most breast cancer panel genes is quite low, or even, in most cases, similar to the
frequency of mutations observed in cancer-free population controls. They con-
cluded that panels have the potential to provide clinical misinformation and harm at
the individual level if the data is not interpreted with extreme caution [14]. This
lack of evidence for new genetic players is not limited to breast and ovarian cancer,
but it also plagues many other genetic diseases and also afflicts a great number of
other multigene panels [19].
Due to this lack of supportive data, international large-scale studies into the
genes included in these multigene panels are absolutely critical to increase the
utility of the information yielded and also to ensure that the new genetic informa-
tion presented is both safe and useful in a clinical setting.
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the time treatment decisions are being made. We can see from the eviQ’s general
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in oncology, genetics plays a large part in the diagnostics of disease [23]. We can
also note that there must be a strong clinical suspicion of the diagnosis involving a
genetic element (e.g., quite young, strong family history, hailing from a region with
restricted gene flow, etc.) to warrant testing and for it to be useful.
The clinical utility of genetics is highly variable and dependent on the gene or
disorder involved, but genomics medicine appears to be very good at revealing a
diagnosis, and, at times, it can help explain why the phenotype is the way it is. In
oncology, genetic testing plays an integral role in disease management by influenc-
ing treatment options or by being a major inclusion component for clinical trials.
Where genetic testing is taking off and, perhaps, where its true potential lies is in its
ability to offer predictive and preventative medicine, particularly for families, as
opposed to adhering to a purely reactive approach that is typically employed in
mainstream medicine.
Genomics is by no means irrelevant; it is revealing much about human disease
and pathophysiology, but barring the current leaps and bounds observed in oncol-
ogy, genomics medicine is still in an informational gathering phase—albeit, it is
doing so at an alarming and unparalleled rate. It will take a great deal more data,
analysis, and time before it will be considered true mainstream medicine, but there
is no doubt that genomics is the future of medicine.
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